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Dear Reader, 
 
This thesis is a combined dissertation of two individual projects undertaken as a 
compulsory part of a research masters degree in molecular and cellular biology. 
 
My first project was under the supervision of Dr. Matthias Soller involving the study 
of a specific type of methylation using Drosophila as a model organism. It involved 
developing a knockout mutant of a gene CG6422 that encodes a YTH domain 
containing  protein which might interact and control neuronal development. The 
project was conducted at the School of Biosciences, College of Life and 
Environmental Sciences, University of Birmingham. 
 
Dr. Luke Alderwick supervised my second project at the institute of microbiology and 
infection at the School of Biosciences, College of Life and Environmental Sciences, 
University of Birmingham. The project involved use of automated liquid handling 
system and highthroughput screening to design and develop a screening assay to 
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Abstract 
Living systems are governed by tightly regulated systems and pathways, which 
determine the survival time, development and period of division of the cell or an 
organism. All genetic information regarding the body is encoded in the DNA of an 
organism, which is processed into functional forms such as RNA or proteins. Several 
pathways involving processing of RNA regulate the synthesis of RNA and protein. 
Among these processes internal methylation of adenosine bases is seen to regulate 
alternate splicing and regulate neuronal development. The proteins binding to these 
methylated sites on the RNA are seen to have a special domain called an YTH 
domain. This study involved developing a knockout mutant of one of such proteins 
containing this domain, which might interact and control neuronal development called 
CG6422. A single knock-out mutant was obtained for the said gene and further 
phenotypic and behavior studies were done to observe a level of neuronal defect. 
Further studies and mapping of the knock-out gene could reveal the exact function 
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1. INTRODUCTION 
 
A genome contains hereditary information in the form of nucleic acid molecules. 
These molecules have discrete functional units; genes, which are the basis to all the 
characteristics that an organism has. Living organisms have genes varying in number 
such as < 500 (for mycoplasma),  >20,000 in humans to around 60,000 in a protozoan 
species (Lewin et. al., 2004). 
The next most important nucleic acid apart from the DNA is the RNA, which plays a 
central role in gene expression. It acts as a central player in converting genetic 
information from the DNA or mainly genes into active proteins, which essentially 
make the organisms work (Evan, 1991).  
There is compartmentalization of the process of conversion of DNA to RNA 
(transcription) and RNA to protein (translation) in eukaryotes by a nuclear membrane. 
The RNA is transported after processing through the nuclear pore into the cytoplasm 
so that translation can occur (Lewin et. al., 2004; Evan, 1991). 
Eukaryotic cells have three types of genetic controls:  transcriptional, post-
transcriptional and translational. 
-­‐ The transcriptional control involves the regulation of pre-mRNA synthesis. 
-­‐ Post-transcriptional modification involves mRNA modification after its 
synthesis in the nucleus, which is important for the regulation of gene expression. 
-­‐ Translational control involves control of intracellular protein synthesis 
(Soller, 2006; Orphanides et. al., 2002) 
 
 










Figure 1. The exons in the figure are depicted as boxes, introns as lines. Alternative 
mRNA processing types are given: The gene on top and mRNA isoforms below. 
Alternative mRNA processing is depicted by dotted lines while constitutive ones with 
solid lines. Adenosine to inosine editing (A to I), have editing site complementary 
sequences (ECS) present in the introns with edited site in the exon (Soller, 2006). 
 
1.1Post	  -­‐transcriptional	  regulation	  
 
The RNA before it is processed is known as a pre-mRNA and undergoes various 
modifications before it forms an mRNA, which is transcribed into proteins. These 
modifications are also termed as post-transcriptional modifications or RNA 
processing. The RNA processing involves modifications such as capping, 
polyadenylation, methylation, editing and splicing as shown in Fig.1. Some of them 
are essential to the formation of mRNA and its function such as capping, 
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polyadenylation and splicing while others are regulated based on their requirement 
(Soller, 2006). 
There is evidence supporting coupled occurrence of pre-mRNA splicing and 3’ 
polyadenylation with 5’ capping processes. It has been biochemically proved that an 
intact 5’ cap is required for efficient splicing and polyadenylation (Orphanides et. al., 
2002). The major player here is the CTD tail of the mRNA, which is phosphorylated 
and dephosphorylated at various stages of transcription and also changes during other 
processing events such as polyadenylation, splicing and capping. (Cowling, 2010).  




Capping of mRNA involves addition of a 7-methyl guanosine “cap” to the first 
transcribed nucleotide. In yeast and humans it has been seen to be important for 
efficient gene expression and viability of the cell. The 7-methyl cap is required for 
translation as it stabilizes the RNA against attachment of exonucleases that destroy it. 
It also helps in promoting transcription and splicing, polyadenylation and nuclear 
export of mRNA. RNA polymerase II is the main enzyme involved which interacts 
with the cap methyltransferase (Cowling, 2010). 
The steps of capping involve a three -step reaction where in a N7 methyl GMP is 
added onto a 5’-5’ triphosphate linkage which is then again bound by a cap binding 
protein complex of 20-80 kDa (Soller, 2006) 
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1.1.2.	  Polyadenylation:	  
 
Polyadenylation occurs at the 3’ end of the pre-mRNA where the consensus sequence 
of AAUAAA hexamer is bound by a cleavage and polyadenylation specificity factor 
(CPSF) and a cleavage stimulatory factor (CstF) binds to a U- or GU-rich downstream 
sequence element (DSE). After cleavage under direction of two additional proteins, 
cleavage factors II and I and poly A polymerase, a tail of about 200 adenosine 
residues is added (Soller, 2006). 
 
1.1.3.	  RNA	  editing:	  
 
RNA editing is a process of creating variation by changing nucleotides in the RNA 
and seems to occur only in eukaryotic cells and in bacteria among prokaryotes. The 
process occurs mainly through deamination of residues, which code for different 
amino acids therefore creating variation. The most common conversion is that of 
adenosine to inosine which is carried out by the enzyme adenosine deaminase acting 
on RNA (ADAR). Another less common editing occurs for cytidine to uridine 
demamination, which is found only in two genes to date. The fact that adenosine 
deaminase acting on RNA-2 (ADAR2) is self-regulatory and changes the splicing 
pattern and that most ECS (editing site complementary sequence) are present in 
introns, it is obvious that RNA editing occurs before splicing and affects it to a certain 
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1.1.4.	  Splicing:	  
 
Splicing involves removal of introns and joining the exons together into a functional 
mRNA ready to be transcribed into a protein in the cytoplasm. It occurs in two trans-
esterification reactions leading to a spliced mRNA while removing introns in a lariat 
loop formation. 
The whole splicing assembly involves consecutive addition of five small 
ribonucleoproteins (Snurps) which are U1, U2, U4 and U6 and other proteins to form 
a complete complex called the spliceosome. On the pre-mRNA a 5’ splice site with a 
consensus sequence, a branch point, a polypyrimidine tract and a 3’ splice site are 
required to splice the pre-mRNA. 
 
Another type of splicing occurs where in splicing out different introns. It can lead to 
variable combinations and diversity in the same RNA sequence therefore, producing 
variety in the proteins that are thus transcribed from these mRNAs. This is known as 
alternative splicing. This involves the presence of a large number of RNA binding 
proteins (RBPs) containing one or more RNA binding domains and at least one 
additional auxiliary domain. In Drosophila, gene specific RNA binding protein ELAV 
is known to bind to the ewg gene. The protein is said to have evolutionary conserved 
domains, which is involved in neuronal regulation (Soller, 2006). 
 
1.1.5.	  RNA	  methylation:	  
 
Capping at 5’ end involves methylation of the initial bases, but many mRNAs 
undergo internal methylation. The major form of internal methylated base is N6 
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methyladenosine, found in eukaryotic mRNA, viral mRNA and retroviral RNAs. 
Although the methylation is sequence specific for Gm6AC and Am6AC, the 
distribution of the methylated bases is random (Kane et. al., 1985). 
The only modification in mRNA capping that is well studied is the m7G having a role 
in translation initiation, mRNA transport, splicing and degradation of mRNA.  
The Eukaryotic mRNA undergoes various types of methylation such as : 
 
• The standard methylation, which occurs during 5’ capping of the mRNA 
strand. It involves the formation of M7G (5’) ppp (5’) N1 (m) pN2 (m) pNpNpN… - 
N7 methylguanosine (m7G) 5’ cap structure at the 5’ end (Fig.2) protecting the 
mRNA from degradation. The length of the cap has been known to determine the time 
and importance of the protein encoded by the mRNA (Jia et. al., 2013).  
 
• The next type of methylation is N6-methyl-2’-O-methyladenosine (m6Am). 
Here, the first position of 5’ termini (N1) and the internal 6th position (N6) are 
methylated. It defines the difference between self and non-self mRNA and is said to 
be the molecular signature of the host (Jia et. al., 2013) (Fig.2). 
 
• 2’-O- methylated nucleoside (Nm) – the first two starting positions at the 5’ 
terminus (N1 and N2) (Jia et. al., 2013) (Fig.2) 
 
• Internal methylation- 
o 5-methylcytosine (m5C) 
o N6- methyladenosine (m6A) (Jia et. al., 2013) (Fig.2) 
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 Figure 2. The structure of various types of methylation in RNA is shown. The green 
ball indicates methylation in the cap and the pink ones indicate internal methylation. 
(Jia et. al., 2013) 
 
Methylation has been found in eukaryotic cell mRNA and viral mRNAs as well. An 
enzyme N6 methylase that methylates mostly internal adenosine sites performs 
internal methylation of pre-mRNA. On an average 1-3 adenosine residues are 
methylated in an mRNA and they occur both in introns and exons, which proves that 
the process occurs before splicing. The function of this type of methylation is not 
clearly indicated though it has been seen to have a role in nuclear processing of 
mRNA. The selection of the internal adenosine residues is partially governed by the 
recognition of consensus sequences such as GAC or AAC (the underlined residue 
being methylated). Although, only a subset of these sequence get methylated 
additional sites and sequence constraints play a role in site recognition. Recognition 
of specific sites for m6A methylation has only been found in bovine prolactin and 
Rous sarcoma virus (Rottman et. al., 1994) 
the mechanism of methyl transfer is likely the conserved
SN2 type reaction from SAM to the amino group of
adenosine, based on the high similarity of the catalytic
domain of MT-A70 to those of the other methyltransfer-
ase enzymes (Figure 3) [31]. MT-A70 colocalizes with
nuclear speckles in HeLa cells, which indicates that the
methylation may happen cotranscri tionally. Loss of
MT-A70 does not lead to cell cycle arrest, but appears
to cause cell death, highlighting its critical role in mam-
malian cells [17].
Because the presence of a methyl group at the N6
position of adenosine does not alter its Watson–Crick
base-pairing property, m6A cannot be mapped by reverse
transcription-based methods, which hindered the function-
al study of m6A in mRNA [32–35]. So far, only 13 m6A base-
resolution sites from RSV viral RNA and one m6A site from
the cellular mRNA bPRL have been mapped, despite the
fact that this modification has been known for more than
30 years [25–28]. Two approaches were applied to probe






















































TRENDS in Genetics 
Figure 1. Modifications in eukaryote mRNA. The structure and localization of RNA modifications in mRNA are shown. N7-methylguanosine (m7G) is at the 50 terminus of the
cap structure, N6-methyl-20-O-methyladenosine (m6Am) at the first position of the 50 terminus and internal positions, 20-O-methylated nucleosides (Nm) on the first two
starting positions of the 50 terminus and internal sequence, and 5-methylcytosine (m5C) and N6-methyladenosine (m6A) are internal mRNA modifications (green ball
indicates the modifications located at the cap, pink ball indicates internal modifications).
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Figure 2. The history of the research on N6-methyladenosine (m6A) in mRNA.
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The most prevalent internal methylation is the m6A methylation and its role is still 
quite unclear. This type of methylation was first found in mammalian mRNA in the 
mid-1970s. It was found in eukaryotes mainly animals, plants, flies, yeast in its 
meiotic state and viruses (mainly the Rous sarcoma virus). 
 
The m6A methylation is done by N6 methyltransferase which is a complex of 200kDa 
having a 70kDa SAM binding subunit structure called MTA70. The remaining 
structure has not been characterized. The identification of internally methylated sites 
was difficult early, as the internal methylation does not alter its base pairing property. 
Therefore the internal m6A could not be mapped using RT base methods (Bokar et. 
al., 1997). 
 
The m6A sites are highly conserved in humans and mouse. In yeast though 
methylation is only detected during meiosis and not in the mitotic phases. A study 
showed that when yeast enters meiosis m6A methylation increases. Also, they 
indicated that it decreased when the yeast was growing in a low nutrition medium as 
opposed to a high one and increased when the nutrition was increased. Therefore, the 
internal methylation controls the fate of meiosis in yeast cells. 
M6A methylation was found in monocot plants such as maize, wheat, and oats around 
30 years ago. It has been widely studied in Arabidopsis where it is around 1.5% in 
ratio (m6A to A) (Bodi et. al., 2010; Jia et. al., 2013). 
m6A modification in Drosophila was first discovered in 1978. A study on the MT-
A70 homolog in drosophila Dm ime4 showed expression in ovaries, which localize in 
germ line cells in ovaries and somatic cells as well. Complete deletion of Dm ime4 
proved lethal for the organism and therefore showed that the gene was essential for 
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organism viability (Jia et. al., 2013). 
As mentioned above the internal methylation on adenosine was difficult to detect 
which has stunted the study of this type of methylation and its function for a long 
time. A method for detection of methylation by immunoprecipitation has been 
deduced using anti- m6A anitbodies against digested RNA transcripts. After which 
the precipitated molecules can be sent in for sequencing. Domissini et. al., (2012) 
have deciphered a consensus sequence, which is found in methylated RNA, shown in 
the fig.3 along with the above said method. This methylation is said to have some 
regulatory roles due its variable presence in various RNA transcripts.  
            The consensus sequences were found in higher concentration at the 
transcription start site (TSS) and the 5’ UTR and stop codon. It was also observed that 
m6a methylation was increased in genes that were moderately expressed as compared 
to genes that are very highly expressed or have very low expression. m6A 
methylation has a role in splicing as well, as it is correlated with methylation of multi 
isoform genes and alternate splicing (Fig.3).  
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Figure 3. m6A – seq capture of modified RNA fragments exposes an enriched motif. 
a. Diagram representing the method used to detect m6A methylation using anti-m6A 
Ab and immunoprecipitation.b. Consensus motif representing by the sequence 
logo.c.Density plot describing the distribution of distance between the peaks of 
m6A/control fragments and the nearest m6A consensus motif (RRACU) (Dominissini 
et. al., 2012) 
 
 
Meyer et. al., (2012) confirmed the presence of m6A methylation being higher at the 
3’ UTR and stop codon region as compared to the 5’ UTR. The importance of m6a 
methylation in regulatory roles was confirmed by the demethylase activity of the 
human FTO (Fat mass and obesity associated) gene, which is responsible for cause 
metabolic diseases and increasing obesity in humans. The occurrence of m6A 
methylation in 3’UTR is significant as the region is valued for its role in RNA 
such as lincRNAs and antisense RNAs—comprising the first m6A
RNA methylome (Supplementary Tables 1, 6 and Supplementary
Link 1). This number probably underestimates the actual number
of m6A sites (Supplementary Fig. 3).
Repeated analysis using the model-based analysis of ChIP-seq
(MACS) peak-calling algorithm based on genome-aligned reads iden-
tified 20,401 peaks (FDR # 5%, fold change $ 4), containing over
96% of the transcriptome-based peaks, among them 1,508 intron
peaks (Supplementary Table 3).
The high specificity and immunoprecipitation compatibility of the
antibody used are well established and have been described in a
multitude of publications9,16–22. Several additional measures were
taken to ensure the validity and stringency of our experimental
approach (Supplementary Note 1), in addition to identification of a
known m6A site within 18S rRNA23.
To determine whether our identified m6A peaks share a common
sequence element potentially specifying methylation, we performed
an unbiased search for motifs enriched in regions surrounding m6A
peaks (Methods). Clustering of all significantly enriched sequences
perfectly recapitulated the previously established RRAC core, and
revealed a terminal U to be a dominant part of the consensus
(Fig. 1b and Supplementary Fig. 4). The median distance between
m6A peaks and the consensus sequence was 24 nucleotides, compared
to 117 nucleotides in control peaks, supporting the specificity of m6A-
seq and r flecting its r solution (Fig. 1c). The identification of a s rong
consensus reinforces the authenticity of the newly discovered m6A
peaks, and supports the existence of a predominant methylation
machinery.
Our results show that the HepG2 transcriptome contains ,1 m6A
peak per 2,000 nucleotides (Supplementary Fig. 3), or ,1.7 peaks per
gene. These results are in line with previous estimations of ,3 m6A
residues per average mRNA transcript in mammalian cells, which
largely relied on the gross proportion of m6As out of all methylated
nucleosides24. Of note, as transcripts are fragmented before immuno-
precipitation, the m6A-seq analysis is blind to methylation patterns at
the single transcript level, but rather produces a gene-specific methy-
lation profile based on fragments derived from the entire transcript
population of a given gene.
Given that the determined consensus is far more prevalent than the
actual observed frequency of m6As by an order of magnitude, other
structural elements, sequence determinants and/or processing steps
might be necessary to specify a site for methylation. A previous small-
scale computational prediction suggested that m6As lie within the
loop of a stem–loop structure3. However, using RNAfold, we were
unable to identify strong secondary structures in regions harbouring
newly identified m6A peaks.
As can be expected from such widespread occurrence, no func-
tional category (GOTERM_MF_1-5) was found to be enriched in a
gene ontology (GO) analysis, suggesting that m6A has a fundamental
function.
m6A distribution reveals a unique topology
Having exposed a new layer of RNA modification, the next challenge
is to infer putative functions. To this end, we began by systematically







































































































Figure 2 | The transcriptome landscape of m6A reveals a unique topology.
a, Metagene profiles depicting sequence coverage in windows surrounding the
TSS (left) and stop codon (right). Coverage of m6A IP and control (input)
fragments is indicated in blue and red, respectively. To normalize for expression
levels, coverage for each position is divided by the mean coverage in the control
experiment. b, Top, pie chart presenting the fraction of m6A peaks in each
of five non-overlapping transcript segments. Middle, relative enrichment of
m6A peaks across transcript segments. Bottom, schematic of the five segments.
c, Density plot showing the distribution of m6A/control peaks according to
exon length. d, Fraction of genes with m6A peaks in each of the segments as
a function of expression level. e, Representative gene transcripts harbouring
m6A peaks. Colour codes are the same as in panel a. Peaks are highlighted
in yellow. Black dashed lines signify CDS borders; transcript architecture is
shown beneath, with thin parts corresponding to UTRs and thicker ones
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Figure 1 | m6A-seq capture of modified RNA fragments exposes an
enriched motif. a, Schematic diagram of the m6A-seq protocol. ab, antibody;
nt, nucleotide. IP, immunoprecipitation. b, Sequence logo representing the
deduced consensus motif following clustering of all enriched motifs. c, Density
plot illustrating the distribution of distance between the peaks of m6A/control
fragments and the nearest m6A consensus motif (RRACU).
RESEARCH ARTICLE
2 0 2 | N A T U R E | V O L 4 8 5 | 1 0 M A Y 2 0 1 2
Macmillan Publishers Limited. All rights reserved©2012
	   19	  
stability, subcellular localization, and translation regulation. These processes involve 
RNA binding proteins, which bind to consensus sequences and other elements in the 
3’UTR. The presence of methylated nucleotides can affect regulation of mRNA by 
modulating the ability of RNA binding proteins to the RNA. 
 
1.2	  RNA	  binding	  proteins	  
 
Recent analysis on m6A RNA for identification of novel m6A binding proteins 
revealed interaction of proteins with YTH domains and ELAV proteins that bind to 
the methylated base (Dominissini et. al., 2012). Proteins with YTH domains are 
conserved in most eukaryotes and bind to RNA functioning mostly in regulating gene 
expression (Zhang et. al., 2010).   
 
In humans, genes HuB, HuC, HuD and HuR belong to the family of neuron-specific 
genes called the nELAV gene. These were detected as targets for autoantibodies in 
patients with paraneoplastic neurological disorders. When the nELAV genes were 
cloned, sequenced and run against the sequence database, orthologous genes in 
Drosophila melanogaster were found. These genes were the embryonic lethal 
abnormal visual system genes, which code for neuron-specific nuclear RNA binding 
proteins (RBP), which regulate alternative splicing in mRNAs. Deletion of these 
genes leads to embryonic lethality and defects in the nervous system imparing the 
neuropil therefore symbolic of its name (Pacsale et. al., 2007). The ELAV protein 
family in Drosophila has three proteins ELAV, Rbp9 and Fne (Toba and White, 
2008). An ortholog of the gene has been recognized in C. elegans, while a 
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corresponding family is also present in the vertebrates, zebrafish and Xenopus 
(Pascale et. al., 2007). Splicing efficiency of protein acting on specific splice sites and 
their stability is affected by ELAV. One of the important roles of ELAV is generation 
of isoforms of proteins in neurons and ensuring that they are correctly spliced. It is 
seen to interact with three main genes ewg, nrg and arm. While its function is best 
understood in relation to the ewg gene, the others are thought to have some role in 
neural development (Koushika et. al., 2000). 
 
The major target of the ELAV proteins is the transcription factor gene ewg, which 
restricts the synaptic growth at neuromuscular junctions (NMJs) (Huassaman et. al., 
2008). ELAV proteins have a characteristics structure with three RRMs wherein the 
second and third RRMs are separated by a “hinge” region of 60-80 amino acids (Toba 
and White, 2008).. The three RRMs are highly conserved wherein RRM3 is less 
conserved compared to the other two (Soller et. al., 2010). The ELAV protein 
interacts with RNA by multimerization and that RRM3 is important for the protein to 
form a complex multimer. Also RRM3 seems to interact with both proteins as well as 
RNA through a bi-functional domain (Toba and White, 2008). The RNA binding part 
of the ELAV is conserved in 12 species of Drosophila with very few amino acid 
changes (Soller et. al., 2010). The RRM domains have two important consensus 
sequences RNP1 and RNP2 for binding to RNA (Zhang, 2010). The RNP 
(Ribonucleoprotein) are embedded in a larger protein domain of 80-100 amino acids. 
The ELAV proteins have three such RNA binding domains, containing an amino 
terminal rich in alanine and glutamine (Yao and White, 1999). Both these proteins 
have consensus sequences, and an octapeptide sequence for RNP1 and a hexapeptide 
sequence for RNP2 but the RNP2 sequence is less conserved compared to RNP1 
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(Robinow et. al., 1988). In the ELAV protein binding to the ewg gene, the 3’ site 
shows higher affinity to binding and helps in complex formation. Splicing in neurons 
and binding capacity is regulated by presence of a U rich region in the ewg. It seems 
that unique sequences do not deduce the binding sites, but they provide prospect for 
combinatorial binding and multiple binding modes of ELAV proteins to the RNA as 
well as other RNA binding proteins (Soller et. al., 2010). 
 
In recent times, Zhang et. al., 2010, observed a highly conserved domain for RNA 
binding. It was identified by comparing it with the splicing factor YT521-B therefore 
the domain was named YTH. The YTH domain is located at the center of the protein 
and has properties similar to RRM and has RNA binding capacity (Stoilov et. al., 
2002). The domain has amino acids from 100 to 150 and is characterized by 14 
invariant and 19 highly conserved residues. The proteins from this family that are 
only found in vertebrates have roles in alternate splicing and molecular regulation. 
Splicing requires three essential conserved residues in the YTH domain for selecting 
the correct splice sites. There are 14 residues seen conserved throughout the 
evolutionary tree which when tested are responsible for detection and selection of 
splice sites. It was seen when the residues of this region were mutated the proteins 
were unable to regulate splice site selection. The multimerization and complex 
formation is facilitated by the ability of the YT521-B carboxyl terminal binding to 
each other. (Zhang et. al., 2010). The YTH domain proteins bind to m6A-methylated 
sites on RNA therefore influencing regulation and splicing of pre-mRNA molecules. 
(Dominissini et. al., 2012). 
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1.3	  Role	  of	  m6A	  methylation	  in	  translation	  
 
Formation of a peptide sequence from an mRNA utilizing ribosomal machinery is 
defined as translation. The m6A methylation is to quiet an extent responsible for 
mRNA splicing, processing and transport as it occurs in the 3’ UTR region. Therefore 
it regulates the production of particular proteins to an extent, which in turn affects the 
translation process. (Carmody and Wente, 2009) although this functional effect is still 
not proven and can be detected if the methylation does not occur of if regulatory 
proteins such as ELAV proteins or proteins with an YTH domain are not produced to 
help in regulation. This would probably lead to a level of phenotypic features, which 
can be analyzed. 
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2. RATIONALE OF STUDY 
 
The proteins involved in m6A methylation and the process itself are conserved within 
eukaryotes. Therefore to study various effects of these proteins on the organism 
development we need to utilize a stable model organism comparable to the human 
system. Biological pathways of humans and fly genomes show a high degree of 
conservation (Bilen et. al., 2006). Drosophila melanogaster has been studied as a 
model organism for more than 100 years now, and is still considered the best 
organism for comparing human biology. It is the best model for comparing the 
molecular and cell biology, genetics and even behavioral patterns such as circadian 
rhythms, geotaxis etc. which are similar to humans. For human diseases proteins can 
be manipulated to see the effect on the fly, which has worked for many human 
neurodegenerative diseases (Beckingham et. al., 2005).  
As explained above, the role of ELAV proteins and proteins with YTH domains are 
still quiet unclear. In order to study their roles in neural development the genes 
producing YTH domain containing proteins that are thought to interact with m6A 
methylated RNA was knocked out. DNA contains mobile elements, which move 
around in the genome causing disruption of genes, called transposons. They are 
present in eukaryotes and their family consists of more than hundreds of such genes. 
They tend to replicate and increase in number within the genome. (Lynch and Conery, 
2003). The main aim of this experiment is to allow disruption of the CG6422 gene via 
transposons. This should result in reduction or alteration in regulatory function of 
mRNAs in neural cells. The lab already has knockout mutants for a subunit of the 
methylase gene, which has certain phenotypic features. The knock out mutants for 
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YTH domain containing proteins from the gene CG6422 in drosophila should also 
give certain phenotypic features, which is compared to the dMTA70 mutant line 
(Clancy	   et.	   al.,	   2002; Meyer et. al., 2012; Robida et. al.,). CG6422 belongs to the 
YT521-B like family which affect splicing by selection of splice sites in vivo 
(CG6422). 
Epitope tagged transgenes for the dMTA70 have been created which when stained 
with fluorescent antibody for epitope-tags and ELAV may detect development of 
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3. AIM AND OBJECTIVES	  
	  
	  





1. Generate knockouts of CG6422 (96B17) by imprecise excision of nearby 
transposable elements. 
 
2. Analyse phenotype of these mutants and compare with phenotypes of other 
flies (Wild type and ELAV mutants dMT-A70). 
 
3. Analysis of dMT- A70 expression in 3’ epitope tagged transgenes in larval 
brains. 
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4. MATERIALS AND METHODS  
3.1	  Fly	  Stocks	  And	  Maintenance	  
Fly stocks and the experiments were maintained and conducted at 25°C on a 12:12 hr. 
light: dark cycle at a constant humidity using a standard sugar-yeast medium. 
 
3.1.1	  Preparation	  Of	  Fly	  Food	  
Requirements: For 1.75 litres of food : Water- 1700 mL,Agar- 18.0 g,Nipagin- 50 
mL,Dextrose- 150g, Cornmeal- 170g, Yeast- 30g (+ 20 %) - 36g 
Procedure: The mixture was boiled till the agar is dissolved and homogenously mixed 
with the other components and dispensed in clean vials at a volume of 10mL. The 
food was then allowed to cool and solidify following, which it was plugged using 
sterile cotton plugs. The food was then stored at 4°C until use. 
 
3.1.2	  Fly	  Stocks	  (From	  Bloomingtion):	  
 
• EP 21985: w118, P {EPg} HP 35572  
Transposable element insertion site; P {EPg} – inserted element; similar to P {EP} 
but modified to work in female germ line; Mobile activating element 8.057Kb 
 
• CxD TM3Sb; w118; TM3, Sb1/CxD 
White eyed flies with chromosome 3 effectively balanced and has the stubble hair 
marker, crossing over strongly reduced in chromosome 3 except distal half of 3L 
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• 24998 TM3Sb Df; w118; Df (3R) BSC 494/TM6C, Sb1, Cu1 
Df (3R) BSC 494- chromosomal deletion, has a stubble marker 
 
• T36 – White eyed flies with two balancer markers, for stubble bristles and 
tubby larva 
 
3.1.3	  Identifying	  Flies:	  
 
 
Figure 4. A. Sex differentiation with male flies having sex combs, penis and a genital 
arch while females have a vaginal plate and virgins have a meconium spot on the 
abdomen. B. Multitude of phenotypes from body colour, bristle type, wing type and 
shape, larval size. C. Difference between a wild type bristle and stubble bristles. 
(Song et. al., 2007) 
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Phenotypic identification of flies was done using comparative study referring pictures 
and microscopic study of flies. 
Male and female sexing of flies is done on basis of presence of sex combs on the fore 
legs of males and identifying a black patch at the dorsal hind region of the fly. Also 
generally male flies are smaller than female flies. 
The crossing scheme involved getting female virgins to set up crosses which were 
identified by the presence of a meconium as shown in the figure above. Female 
virgins generally are lighter in comparison to older flies and can be collected at 
regular timings, as they do not sexually mature within 8-12 hours of emergence.  
There were other phenotypic features, which were to be identified such as stubble 
hair, tubby markers. The stubble hair marker was identified by the presence of short, 
thick bristles on the thorax as opposed to long tapered bristles seen in wild type flies 
as in the above-mentioned figure. 
The tubby markers are hard to identify in adults but can be easily detected in the 
larval or pupal stages, as they are much smaller and fat compared to non-tubby ones. 
In adult flies these are differentiated using the presence of dark patches on the thorax 
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3.2	  PCR	  Screening	  
3.2.1	  Primer	  Designing	  
 
Primer pairs were designed to aid screening of the knock out mutant flies. 





PRIMER SEQUENCE PRODUCT SIZE  
CG6422 
F1 






















   
F3 R2 
F4 R3 F5 R4 




















Table 1. Representing the designed primers with names, sequence and product size. 	  
	  
3.2.2	  Single	  Fly	  PCR	  	  
	  
Requirements:	  PCR Mastermix - Water  - 42 µL; 10x Buffer – 5 µL; dNTPs – 1 µL ; 
Taq Polymerase enzyme – 0.3 µL; Primers – 1 µL each. Dispense 47 µL of the 
mastermix into each tube. 
The single fly PCR involves using a fly as a source of DNA directly. 
Procedure: 
A single male fly (because female flies might have stored sperm which can act as a 
DNA aberration) was selected and put in a pcr tube. The fly was killed in the tube by 
placing it at -20°C for at least 30 min. 200μL of isopropanol was added and the tube 
was incubated for an hour at RT. The tubes were then put in a Speedvac for 30-45 
min at 65°C or till dry. The forward and reverse primers were individually pipetted on 
the walls of the tube without mixing them. The mastermix was added to the tubes, 
while simultaneously washing down the primers on the walls into the mix. The PCR 
mix with the fly was placed into the thermocycler after a quick spin. 
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PCR Program 
30” 94 oC  (Initial Denaturation) 
30” 94 oC  (Denaturation ) 
40” 56-60 oC (Annealing) 
45” 72 oC  (Extension) 
120” 72 oC (Final Extension) 
∞   4 oC (Final Hold) 
 
3.2.3	  Agarose	  Gel	  Electrophoresis	  
 
To run the PCR samples Agarose gel was prepared at a 2% concentration. 
Requirements: Agarose -2g, Distilled water -100ml, Ethidium Bromide - 5µL per 100 
mL, Loading Dye/ Blue Juice (Bromophenol Blue, Xylene Cyanol, Glycerol, EDTA, 
Tris), 100bp Ladder (Fermentas) 
Procedure: 
Add agarose to water in a 250mL conical flask. Heat the suspension until the agarose 
dissolves to get a clear uniform solution. Let the solution cool without solidifying and 
add the ethidium bromide solution. Place combs in the gel tray and pour the solution 
after thorough mixing. Let the gel solidify and remove combs. Store at 4°C until use. 
The PCR samples were run in TAE buffer (1x) using a loading dye (2 μL) with 10 
μL of sample. 4 μL of a 100bp ladder was used. The gel was run at 300V for 20-
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3.3	  	  	  Negative	  Geotaxis	  
	  
Knockout mutant flies were tested for neural problems in comparison to wildtype flies 
using this assay. 
Ideal setting for experiments – Room should be at 25°C and light source (should be 
ideally above). 
The assay should be carried out at the same time of the day, as activity of the flies 
change throughout the day and males and females should be separately tested. 
Procedure: 
3x 15 appropriately aged flies per genotype (in this case 2 genotypes) were taken and 
anesthetized with co2 and put in adapted 25ml pipettes to be used as vertical climbing 
columns. The top and bottom of the pipette were closed with cotton. The	  flies	  were	  
then	  allowed	   to	   recover	   for	  30	  minutes	  at	  25°C	   in	  an	   incubator	  before	   starting	  
the	  assay.	  
Pre-Assay training period: the flies were trained once before the assay was started; 
where the flies were tapped to the bottom (with the same number and intensity of the 
taps) and allowed to climb for 45 seconds. 
Assay: Flies were then again tapped to the bottom and allowed to climb for 45 
seconds. Upon whose completion the numbers of flies above the 25mL line and below 
the 2mL were recorded. This	  was	  repeated	  consecutively	  for	  2	  more	  times	  for	  all	  
the	  3	  sets	  for	  each	  genotype.	  
Analysis: The climbing ability was then calculated by a performance index (PI) given 
by – 
 
	   33	  
	  
Performance Index (PI) = 0.5 x  (n total + n top- n bottom) / n total 
 
N total = total number of flies 
N top = total number of flies at the top 
N bottom = total number of flies at the bottom 
 
3.4	  Larval	  Brain	  Staining	  For	  DMT-­‐A70	  Mutant	  Flies	  With	  3’	  
Epitope	  Tagged	  DMT-­‐A70	  Mutants	  
	  
Requirements: Forceps, PBS, PBT (PBS + 0.1%Triton X), Fix, 1° Antibody [2 types: 
1:20 anti- ELAV (in rat) + 1:50 anti- HA (in mouse) + 10% NGS + 0.1% Sodium 
acetate in PBT]; 2° Antibody: [1:200 anti-rat (Red) + 1:200 anti- mouse (Green) + 
10% NGS + 0.1% Sodium acetate in PBT], Glass slides, Cover slips 
Procedure: 
Selected non-tubby larva and placed them in PBS. Dissected the larva by splitting 
them in half and inverting the skin over the other forcep by holding the mouth hooks 
(Basically turning the larva inside out). Fixed the larva by adding 200 μL of the fix 
for 30 minutes. Washed with PBT for 3x for 10-30 min each. Added the 1o antibody 
and keep it 4°C overnight. Removed antibody and washed the larva with PBT 3x for 
10-30 min. Added the 2° antibody and kept in dark for 4 hours. Washed after 
removing 2° antibody. Checked staining under fluorescent microscope. If the staining 
was satisfactory, the brain attached to the head was neatly and carefully removed, 
clearing the eye and leg discs without damaging the brain. 
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The brains were neatly aligned on the glass slide. The mouth hooks were placed on 
four corners on the slides around the brains. Vectashield was added and the coverslip 
was placed on the mouth hooks, carefully not squashing the brains. Viewed under the 
fluorescence microscope and then transferred to a confocal microscope. 
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4.	  RESULTS	  
4.1	  Creating	  A	  Knock	  Out	  In	  CG6422	  By	  Imprecise	  Excision	  Of	  A	  
P-­‐	  Element	  
	  
The fly stocks were used to put up crosses as per the crossing scheme to get knock out 
mutants for my gene of interest that is CG6422. The gene CG6422 has another gene 
sequence CG3115 being transcribed in the opposite direction. The gene CG3115 
might have implications on the knockout, which are yet unclear. 
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Figure 6. Crossing scheme depicting the entire experiments for getting knockout flies. 
w – white eyed, yw- yellow eyed, w+ - transposon, Sb- stubble, Tb – Tubby, [P] – P 
element jumpout, Df – deficiency. The crossing scheme depicts how the genetic 
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The flies from the stocks were used to put up crosses as mentioned above (Figure.6). 
The flies were distinguished using various phenotypic markers and crossed with 
female virgins to get the first generation of offsprings. The flies from these crosses 
can be collected till 17 days after the first fly comes out after which the second 
generation flies start emerging. 
The crosses were labeled by number 1,2,3 etc. and each time they are flipped they are 
labeled as 1A, 1B etc. So when a fly is collected for the single male crosses it is 
labeled for e.g. as 1Ai which means a fly from the first vial of the cross. If another fly 
is collected from the same vial it is labeled as 1Aii. 
4.3	  Single	  Fly	  PCR	  
4.3.1	  Primer	  Check	  By	  Fly	  PCR	  
CG6422 is located between genes smg6 and bai. The gene has another gene CG31115 
in an opposite transcription frame between 862,666 to 864,971bp of the CG6422 
gene. It has been known to have a molecular function similar to S-methyl-5-
thioadenosine phosphorylase activity and might be involved in nucleoside metabolic 
activity (Graveley et. al., 2011; Flybase) 
 
Figure 7: The above figure describes the general position of the gene CG6422 within 
the fly genome. The highlighted arrows in blue depict the gene, with the direction of 
the arrow depicting the direction in which the gene in transcribed. The arrows below 
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in orange depict the RNA transcripts of the gene. The grey parts highlight the gene 
beginning and end alongwith direction of transcription. 
Primer pairs as per figure 5 were used to detect the gene knockout. Below are the 
various PCR results:	  
	  
 
           1        2         3       4        5 
       
 
Figure 8: Agarose gel depicting bands of amplified DNA with respect to specific 
primers used with reference to a 100bp DNA ladder to compare the size of the 
amplified product. 
Primers were checked using wild type flies (WT) and P-element containing flies (EP 
21985) for deciding the correct primers to use for screening. The primers that did not 
go over the transposon were selected to screen out flies with imprecise jumpouts 




1	  -­‐	  100bp	  Ladder	  
	  
2	  –	  WT	  (F1R1)	  
	  
3	  –	  EP	  21985	  (F1R1)	  	  
	  
4	  –	  WT	  (F2R1)	  	  
	  
5	  –	  EP	  21985	  (F2R1)	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4.3.2	  Screening	  Fly	  By	  PCR	  For	  Jump	  Outs	  
	  
	  	  	  	  	  	  	  	  	  	  1	  	  	  	  	  	  	  	  	  	  	  	  2	  	  	  	  	  	  	  	  	  	  3	  	  	  	  	  	  	  	  	  	  	  4	  	  	  	  	  	  	  	  	  	  	  5	  	  	  	  	  	  	  	  	  	  	  6	  	  	  	  	  	  	  	  	  	  	  7	  
 
 
Figure 10. Agarose gel depicting bands of amplified DNA with respect to specific 
primers used with reference to a 100bp DNA ladder to compare the size of the 
amplified product. Absence of an amplified product reports a positive result for this 
experiment. 
 
Male non-stubble non-tubby flies were selected for screening jump-outs. Some of 
them gave bands, which were indicative of precise jump outs while others without 
bands were indicative of imprecise jump-outs. The ones with imprecise jump-outs 
were selective and repeated with the same as well as other primer pairs for 
confirmation (Fig 10).  
4.3.3	  Repeating	  Testing	  With	  Flies	  
 
PCR was repeated for probable jump-out fly crosses by retesting the flies with all the 
other PCR primers designed as per the picture depicted before. 
1	  -­‐	  100bp	  Ladder	  
	  
2	  –	  WT	  (F2R1)	  
	  
3	  –	  3A	  (F2R1)	  
	  
4	  –	  6E	  (F2R1)	  
	  
5	  –	  9A	  (F2R1)	  
	  
6	  –	  5Fi	  (F2R1)	  
	  
7-­‐	  12	  (F2R1)	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Figure 11. Agarose gel depicting bands of amplified DNA with respect to specific 
primers used with reference to a 100bp DNA ladder to compare the size of the 
amplified product. Confirmatory absence of a band against a negative control. 
 
The PCR using the primers F1R1 recorded absence of bands for two of the probable 
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Figure 12. Agarose gel depicting bands of amplified DNA with respect to specific 
primers used with reference to a 100bp DNA ladder to compare the size of the 
amplified product. Using a different combination of primers to check for imprecise 
excision. 
 
The PCR with primers F2R1 flank the right hand side of the transposon recording any 
imprecise jump –outs. As seen above along with the probable flies other fly crosses 
were screened as well resulting only in one correctly imprecise jump-out (Fig. 12). 
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Figure 13. Agarose gel depicting bands of amplified DNA with respect to specific 
primers used with reference to a 100bp DNA ladder to compare the size of the 
amplified product. Absence of a band confirms the presence of an excision from the 
desired gene. 
The primers F3R2 are on the left side of the transposon, absence of a band in the 4th 
lane sample, confirms the presence of a considerable length of the gene being jumped 
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Figure 14. Agarose gel depicting bands of amplified DNA with respect to specific 
primers used with reference to a 100bp DNA ladder to compare the size of the 
amplified product. PCR to check the probable length of the gene fragment, which was 
excised. 
F4R3 primers were used to detect the length and probable region of the jump-out, 
presence of bands in all of them shows that the region of the gene has not jumped out 
(Fig.14).  
 
Figure 15. Agarose gel depicting bands of amplified DNA with respect to specific 
primers used with reference to a 100bp DNA ladder to compare the size of the 
amplified product using different primer combinations to map the excision. 
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All the above-mentioned PCR results were conclusive of an imprecise jump-out for 
one cross (Fig.15). The flies from these vials were selected to put up a stock and to 
map out the jump out length. Stubble flies were selected and crossed with virgin 
deficiency flies in absence of occurrence of virgin stubble flies along with a stock for 
the jump out upon deficiency flies (P/Df) for further testing. 
4.4	  Frequency	  Of	  Jump	  Outs	  
The frequency of flies jump out was calculated as per the number of flies coming out 
per vial and to that the number of jump out flies coming out.  
Before that the frequency for the single flies used to setup the single male fly crosses 
were calculated to be 1.42%, which is a good frequency level.  
The frequency for precise jump out flies was 0.77% as opposed to the imprecise fly 
frequency which came up to 0.52%, which is a very low percentage frequency 
attributed to the difficulty in phenotypic distinguishing and also the possible low 
activity of the P-element transposon on the fly.  
4.5	  Bioinformatics	  Results	  
The CG6422 gene in Drosophila is orthologous to the YTHDF1 in Homo sapiens. 
The gene name stands for YTH domain family protein 1 which is 559 amino acids 
and contains one YTH domain. It forms two isoforms by alternate splicing as opposed 
to the 4 isoforms of CG6422 (A to D). Although the genes are orthologous to each 
other they show very less similarity in sequences in the BLAST results. That is it 
shows 68% identity with 2% query coverage and negligible E value. The YTHDF1 
gene is present on the 20th chromosome in humans. The YTH domain containing 
proteins haven’t been structurally characterized in a crystal but have been 
characterized in a solution as shown in figure 16. 
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Figure 16. Protein 
structure of YTH domain 








The amino acid sequence of CG6422 was compared with another drosophila YTH 
domain containing protein that is YT521-B. The BLAST result of the two sequences 
does not show much identity (around 29%) that might mean that the proteins although 
having YTH domains might not be exactly with the same structure or function. 
4.6	  Negative	  Geotaxis	  
The graph below represents the negative geotaxis variation between the wild type and 
the jump-out deficiency flies. As seen below the flies with jump-outs have lower 
performance indexes in comparison to the wild type flies. Although the major 
difference is seen in case of female flies compared to male flies, the knockout female 
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Figure 16. Negative geotaxis performance index; Females: Wild Type (WT) and P/Df 
and Males: Wild Type (WT) and P/Df (CG6422ΔdMT-A70). 
 
4.7	  Epitope	  Tagged	  Proteins	  From	  3’	  DMT-­‐A70	  Mutants	  
Larval brains staining from epitope tagged non-tubby larva of dMT-A70 are shown 
below. The stains involved are for ELAV (red) and HA (green); both are localized in 
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Figure 17. A. Larval Brain with HA staining. B. Larval brain with ELAV staining. C. 
Superimposed images containing both HA and ELAV stains. 
 
The staining does show nuclear localization strongly in several cells but due to the 
absence of clear nuclear staining for ELAV it cannot be deciphered as to whether the 
developing cells are neurons or not. The results for the above mentioned cannot be 
considered conclusive due to improper diffused staining of ELAV. 
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5. DISCUSSION 
 
The aim of this was to study internally methylated RNA sites and to understand the 
plausible effects of absence of YTH domain containing proteins that interact with 
these methylated sites for regulation and the development of neurons in drosophila. 
As per the experiments conducted one single jump-out mutant was found among 118 
crosses setup for the producing knockout flies.. 
 
The reason for such a low number of jump-out flies could be the presence of the 
position effect in the crosses with the transposon and T36 flies. The flies used to setup 
single male crosses should have been white eyed as per the crossing scheme but 
opposite to expectation the flies that came out have eye colors which were very light 
yellowy almost to white with variable pigmentation. This lead to the conclusion that 
the possible occurrence of position effect and the presence of additional transposons 
might have caused the occurrence of this eye color. Therefore, after this when flies 
were used for screening, the deficiency and tubby have very minute differences in 
phenotype which might have been a key factor to the fact that many samples gave a 
positive result (that is the absence of a band after PCR for imprecise jump out) but 
gave a negative one when retested. This could have been one of the major drawbacks 
for finding only one jump-out. It could also have been that the transposase activity is 
very low which was the reason behind the jump-outs being low in number. 
The jump-out flies, which were found to be positive were used to put up stocks and 
expressed a level of neural disruption as experimented via the negative geotaxis. The 
female flies in the jump-outs show a lower performance index as compared to males. 
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This might be because the P-element flies have a transposon, which is propagated 
through the female line, which could be a reason for the strong neuronal dysfunction 
in females compared to males. The bioinformatics studies of the proteins with YTH 
domain involve CG6422 and YT521 B mainly which although are not identical in 
anyway have similar domains and are supposedly having similar regulatory functions 
in methylated RNA for neuronal development. 
 
Further studies on the same project would involve, mapping the imprecise jump-out 
and therefore getting to know the extent of the gene disruption. This could be taken 
further by developing a complement for the knocked out gene to deduce the effects 
without the gene and on addition of the complement to the cells on neuronal 
development in flies from all stages (larval to adult).  
Studies for sexual development and flight hampering could also be performed. A 
negative geotactic comparison with the dMT-A70 mutants wasn’t performed due to 
shortage of flies, which died over a period of 15-day incubation outside for slow 
growth.  
 
The dMTA-70 epitope tagged transgenes were basically done to study the 
development of larval brain and whether or not the developing calls at the lobes were 
neurons or not. This would have lead to the identification of the fact that absence or 
presence of the methylase enzyme affects regulation and development of neurons. But 
due to the diffused staining of the ELAV protein antibodies no conclusive results 
could be drawn from it. At best repeating the experiment could carry studies forward.  
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The next step in this study after mapping the gene could be producing a 
complementary transgene of the jump-out and then microinjecting these into the 
mutant embryos or larva to see effects on development and adult neuronal status. This 
could give conclusive evidence about the functional importance of YTH domain 
containing proteins along with their role and level of interaction with methylated 
RNA. 
The gene could also be used to produce proteins via recombinant techniques and 
added to the larva to view direct effect of the protein on the larval development, as it 
should interact with methylated mRNA therefore regulating neuronal growth. This 
project has made me think a lot on the newer avenues of neuroscience and neural 
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Figure 1. The exons in the figure are depicted as boxes, introns as lines. Alternative 
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mRNA processing types are given: artificial gene on top and mRNA isoforms below. 
Alternative mRNA processing is depicted by dotted lines while constitutive ones with 
solid lines. Adenosine to inosine editing (A to I), have editing site complementary 
sequences (ECS) present in the introns with edited site in the exon. (Soller, 2006) 
Figure 2. The structure of various types of methylation in RNA is shown. The green 
ball indicates methylation in the cap and the pink ones indicate internal methylation. 
(Jia et. al., 2013) 
Figure 3. m6A – seq capture of modified RNA fragments exposes an enriched motif. 
a. Diagram representing the method used to detect m6A methylation using anti-m6A 
Ab and immunoprecipitation.b. Consensus motif representing by the sequence logo. 
c.Density plot describing the distribution of distance between the peaks of 
m6A/control fragments and the nearest m6A consensus motif (RRACU) (Dominissini 
et. al., 2012) 
 
Figure 4. A. Sex differentiation with male flies having sex combs, penis and a genital 
arch while females have a vaginal plate and virgins have a meconium spot on the 
abdomen. B. Multitude of phenotypes from body colour, bristle type, wing type and 
shape, larval size. C. Difference between a wild type bristle and stubble bristles. 
(Song et. al., 2007) 
 
Figure 5. The primer pair positions are depicted in the diagram with sizes of amplified 
products. 
Figure 6. Crossing scheme depicting the entire experiments for getting knockout flies. 
 
Figure 7. The above figure describes the general position of the gene CG6422 within 
the fly genome. The highlighted arrows in blue depict the gene, with the direction of 
the arrow depicting the direction in which the gene in transcribed. The arrows below 
in orange depict the RNA transcripts of the gene. 
 
Figure 8. Agarose gel depicting bands of amplified DNA with respect to specific 
primers used with reference to a 100bp DNA ladder to compare the size of the 
amplified product. 
 
Figure 9. Agarose gel depicting bands of amplified DNA with respect to specific 
primers used with reference to a 100bp DNA ladder to compare the size of the 
amplified product. Absence of an amplified product reports a positive result for this 
experiment. 
 
Figure 10. Agarose gel depicting bands of amplified DNA with respect to specific 
primers used with reference to a 100bp DNA ladder to compare the size of the 
amplified product. Confirmatory absence of a band against a negative control. 
 
Figure 11. Agarose gel depicting bands of amplified DNA with respect to specific 
primers used with reference to a 100bp DNA ladder to compare the size of the 
amplified product. Using a different combination of primers to check for imprecise 
excision. 
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Figure 12. Agarose gel depicting bands of amplified DNA with respect to specific 
primers used with reference to a 100bp DNA ladder to compare the size of the 
amplified product. Absence of a band confirms the presence of an excision from the 
desired gene. 
 
Figure 13. Agarose gel depicting bands of amplified DNA with respect to specific 
primers used with reference to a 100bp DNA ladder to compare the size of the 
amplified product. PCR to check the probable length of the gene fragment, which was 
excised. 
 
Figure 14. Agarose gel depicting bands of amplified DNA with respect to specific 
primers used with reference to a 100bp DNA ladder to compare the size of the 
amplified product using different primer combinations to map the excision. 
 
Figure 15. Protein structure of YTH domain containing protein in solution. (PDB) 
 
Figure 16. Negative geotaxis performance index; Females: Wild Type (WT) and P/Df 
and Males: Wild Type (WT) and P/Df (CG6422ΔdMT-A70) 
 
Figure 17. A. Larval Brain with HA staining. B. Larval brain with ELAV staining. C. 
Superimposed images containing both HA and ELAV stains. 
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Development of a phenotypic high throughput-screening assay 
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List of Abbreviations 
 
% - Percentage 
°C - Degree Celsius 
ACP - Acyl carrier protein 
ADH - Anti Diuretic Hormone 
AG - Arabinogalactan 
AIDS - AutoImmunoDeficiency Syndrome 
BCG - Bacillus Calmette–Guérin 
DA - Dopamine 
DAT - Dopamine Active Transporter 
DMSO - Dimethyl sulfoxide 
DOTS - Directly Observed Therapy – Short Course 
EMB - Ethambutol 
ER - Endoplasmic Reticulum 
FAD - Flavin adenine dinucleotide 
FDA - Food and Drug Administration 
FLD - First Line Drugs 
G + C - Guanine + Cytosine 
GFP - Green Flourescent Protein 
g - Grams 
HIV - Human Immunodeficiency Virus 
hrs - hours 
HTS - High Throughput Screening 
KAS - β-ketoacyl synthase 
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LAM - Lipoarabinomannan 
LM - Lipomannan 
M.I.C - Minimum Inhibitory Concentration 
MA - Mycolic Acid 
MAC - Mycobacterium Avium Complex 
MDR-TB - Multi Drug Resistant Tuberculosis 
mg/mL - milligram/ millilitre 
mM - millimolar 
NAD - Nicotinamide adenine dinucleotide 
NADH - Nicotinamide adenine dinucleotide (reduced) 
O.D600 - Optical Density at 600 nanometers 
PDIM - Pthiocerol Dimycocerosate 
PIM - Phosphotidyl Inositol Manoosides 
PPD - Purified Protein Derivative 
PTP - Phosphotyrosine phosphatase 
RLU - Relative Light Unit 
RNA - Ribonucleic Acid 
rpm - Revolutions per minute 
SL - Sulfolipids 
SLD - Second Line Drugs 
SSC - Short Course Chemotherapy 
TB - Tuberculosis 
TDM - Trehalose Dimycolate 
TLR - Toll Like Receptors 
TMM - Trehalose Monomycolate 
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TNF - Tumor Necrosis Factors 
UDP - Uridine Diphosphate 
VGCC - Voltage Gated Calcium Channels 
WHO - World Health Organisation 
XDR-TB - Extremely Drug Resistant Tuberculosis 
µg/mL - Microgram/ Millilitre 
  




Tuberculosis is a major cause of death around the world. It has afflicted mankind for 
centuries with its inherent property of remaining dormant within the host system. 
With development of new drug regimens by health administrators all over the world 
the disease was thought to have been under control until the emergence of newer 
strains of Mycobacterium, which are resistant to antibiotics prescribed to combat it. 
Due to the contagious nature of the disease the drug resistant strains have started 
becoming more prevalent leading to problem of treatment due to dwindling treatment 
options. This calls for new drug discovery in the area, which could lead to potential 
for newer drug regimens for treatment of drug resistant strains. In order for quicker 
drug or antibiotic discovery, synthesized compound libraries have been screened 
through highthroughput screening, reducing the gap between the compound discovery 
and activity helping to process drug libraries quickly to get the possible novel drugs in 
use. The aim of this project was to develop a new and efficient assay to be used for 
highthroughput screening of compound and FDA (Food and Drug Administration) 
approved drug libraries. The assay developed was a phenotypic assay based on 
fluorescence level detection correlating to bacterial survival in M. smegmatis 
(mc2155) strain. The results obtained from the work done have led to some novel and 
promising drugs successfully screened using the newly designed and optimized assay. 
Further work has to be done on the mode of action and dose response activities of the 
“hits” achieved from the screens. 
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Koch discovered the causative agent of Tuberculosis more than 100 years, which is 
Mycobacterium tuberculosis. The oldest remains found of tuberculosis were from 
bones of skeletons aged 5400 years, which means the disease was prevalent during 
that time. The bones excavated suggested that the person was suffering from Pott’s 
disease, which is an extra pulmonary form of tuberculosis deforming the spine 
(Curbezy et. al., 1998).  Tuberculosis was also common in Greece, as Hippocrates 
well recognized the disease “phthisis” and could identify its clinical symptoms. He 
described it as consumption in his “Book I, Of The Epidemics” and wrote about how 
it mostly affected young adults proving fatal to more people than any other disease. 
(T.Daniel, 2006).  Later during the 18th and 19th century consumption was considered 
incurable and possibly a hereditary disease as it prevailed mostly among families 
through generations while others debated it to be occurring due to stress and poor 
nutrition (T.Daniel, 2006). Speculations were still ongoing even after Dr. Jean-
Antoine Villemin, proved the contagious nature of the disease by successfully 
transmitting the infection from humans to rabbits (J. F Murray, 2006). It wasn’t until 
Robert Koch presented his famous lecture in Berlin, 1882 on Die Aetiologie der 
Tuberculose that the exact cause of the disease was recognized. A few years later, he 
isolated a substance from the bacilli which when injected gave an immune response 
therefore proving itself as a probable diagnostic, the substance was called tuberculin 
(ref). The test was further improvised over the years, such as Charles Mantoux 
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introducing the protein intracutaneously using cannulated needles and Florence 
Seibert developing purified protein derivative (PPD) (T. Daniel, 2006). It still remains 
one of the widest known afflictions to mankind due to its resilient nature and clever 
strategies of survival, which circumvents the host immune system. This makes 
Mycobacterium tuberculosis, the causal organism of tuberculosis a very successful 
pathogen (I. Smith, 2003; Mukhopadhyay et. al., 2011). 
1.2	  Classification	  
	  
The origin of Mycobacterium tuberculosis is thought to have been from a progenitor 
species of actinomycetes existing in soil, which evolved to live reside in a mammalian 
host. The domestication of cattle around 25,000 years ago would have lead to the 
transmission to humans by evolutionary development into M. tuberculosis. Early 
hypothesis of the development of M. tuberculosis from M. bovis was falsified in view 
of recent genomic experiments, which prove that M. tuberculosis developed from 
other Mycobacterial complexes such as M. africanum, M. microti, and M. canetti, as 
well as M. tuberculosis and M. bovis which affect both humans and animals equally 
(I. Smith, 2003). Due to the high level of similarity within the housekeeping genes 
between the M. tuberculosis complex it is thought that the species underwent an 
evolutionary slow down around 15000-20,000 years ago (Brosch et. al., 2002). 
Mycobacterium complex is classified under the family Mycobacteriaceae that is 
reflected by the presence of high percentage long chain fatty acids called mycolic 
acids in its cell wall.  It is further encompassed under the order of Cornybacterineae 
defined as an acid-fast bacilli with a high G + C content. The order is Actinomycetales 
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and phylum Actinobacteria, which are defined by being aerobic gram positive 
bacteria with a genetic composition rich in guanine and cytosine and cell walls 
containing peptidoglycan and mycolic acid (Minnikin, 2002). 
1.3	  Pathogenesis/Immunology	  
 
The infection by Mycobacterium tuberculosis is transmitted from person to person by 
droplet nuclei about 1-5µm in diameter, which are dispersed in air by coughing, 
sneezing, speaking and singing. The bacilli in these nuclei are airborne for a long 
period of time but this might not necessarily mean that people coming in contact will 
be infected by it. There are four major factors governing the infection, a. number of 
organisms expelled by an infected person in the surrounding, b. concentration of the 
bacilli within that volume of air and the ventilation level in the area, c. length of 
exposure to the contaminated air by a person and d. the immune status of the person. 
The droplet nuclei when inhaled by a person transport the bacilli via the pharynx to 
the bronchial tree and to the bronchules or alveolus. The establishment of the 
infection depends on the immune strength of the person. Mycobacterium is not known 
to have any endo – or exo-toxins therefore do not cause an immediate immune 
response, especially if the bacterial load is very low. The bacteria resides within the 
alveoli and multiplies over a period of few weeks to a bacterial count of 103 - 104 
which then triggers the immune response in the host. The primary immune response 
in a host is lead by attack of the alveolar macrophages on the bacilli. The tuberculosis 
bacteria has a special mechanism of survival unlike other bacterial pathogens, 
therefore instead of evading the macrophages the bacilli seeks entry into the 
macrophage phagosome utilizing several surface receptors and once inside it modifies 
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the maturation of the phagosome, increasing its survival percentage (Dunlap et. al., 
1999; M.S Glickman and W. R Jacobs, 2002). 
Invasion of macrophages and phagocytosis of the bacilli releases an inflammatory 
reaction causing recruitment of mononuclear cells to form granulomas. Granulomas 
are mainly epicenters of infection containing the infected macrophage at its nuclei 
surrounded by foamy giant cells, lymphocytes on the periphery to contain the 
infection. While within the macrophage the bacilli applies various strategies such as 
not allowing the fusion of the lysosome with the phagosome or acidification of 
phagosome, resistance to killing by oxygenated metabolites. The bacteria, therefore 
counters the microbicidal activity of a macrophage to form an environment to suit its 
own survival (J.Basu, 2004). The struggle between the bacterial survival and the 
immune system continues forming what is called a caseating tubercle, where some of 
the bacilli come out into the extracellular mileu of the cellular debri. The caseating 
necrosis is still surrounded by T cells and activated macrophages to contain the area 
of infection. In case of immunocompetent hosts with a robust immune system the 
activated macrophages and cytotoxic T cells are efficiently engaged. While for hosts 
with a weaker immune system the activated macrophages are not efficiently supplied 
which leads to non-specific destruction of lung tissue. The infection can necrotize into 
the blood vessels, which disseminates the bacteria to other parts of the body leading to 
extrapulmonary tuberculosis. If the infection necrotizes in the bronchiole the host can 
then actively transmit infection to other people via droplet infection (Curtiss And 
Haydel, 2003). 
Statistically most healthy people have an asymptomatic infection of mycobacterium 
tuberculosis, which becomes symptomatic only in 10% of cases and remains latent for 
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90% of the time. Clinically latent forms of tuberculosis can be defined as infected 
people who are not symptomatic and cannot spread the disease. They can only be 
detected by a positive tuberculin test. A person with a delayed type hypersentivity to 
the PPD test without actual symptoms of tuberculosis is said to have latent 
tuberculosis.5-10% of people with latent infections develop an active infection during 
immunosuppressed conditions caused due to chemotherapeutic stress, other disease 
conditions and age (Curtiss and Haydel, 2003, Tufariello et. al., 2003). 
1.4	  Epidemiology	  
 
The disease is known to cause death of around 1.5 million people a year worldwide, 
out of which most of them occur in developing countries. With the increase in the 
number of immunocompromised people due to the higher cases of HIV and AIDS, 
around 19-43% of the world’s population is infected with Mycobacterium 
tuberculosis (Fleischman and Greenberg, 1998; Flynn and Chann, 2002; Dumlap et. 
al., 1999) Fig.19. Around 15 million people in the U.S have been diagnosed with 
tuberculosis in the past few years (Lawn and Zumla, 2011).  
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Figure 19: The prevalence and incidence rates of tuberculosis in 2009. A. Estimated 
rates of tuberculosis; B. Estimated HIV prevalence in new tuberculosis cases (Lawn 
and Zumla, 2011). 
The World Health Organisation (WHO) came up with a strategy to control 
tuberculosis by a controlled drug therapy program called DOTS (Direct Observed 
Treatment). The program had five key elements involving political commitment to 
Seminar
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these cases were in sub-Saharan Africa (about four of 
every fi ve cases) and southeast Asia (fi gure 1).4 HIV has 
fuelled a three to fi ve times increase in tuberculosis 
incidence rates in many high HIV prevalence countries 
in sub-Saharan Africa (fi gure 2), especially in the south 
and east of the continent.2,5 In the worst aff ected countries 
of South Africa and Swaziland, about 1% of the population 
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Figure 1: Tuberculosis incidence and prevalence rates in 2009
Estimated tuberculosis incidence rates (A). Estimated HIV prevalence in new tuberculosis cases (B). Reproduced from Global tuberculosis control.4
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areas majorly affected with Tb, detection of case by sputum analysis, short course 
chemotherapy (SSC), case management by direct observed treatment and recording 
and reporting of cases. The DOTS program dramatically increased the control of 
tuberculosis (Gupta et. al., 2001). SSC was the most effective treatment regimen that 
was planned, wherein patients were treated over a period of 6-8 months with drugs 
while continuously observing symptoms and microscopic analysis of the sputum. 
Along with that preventive therapy was suggested to high-risk patients who could 
easily contract tuberculosis due to a low immune strength such as people with HIV. It 
was estimated that by 2010 the success of the DOTS program would be observed by 
23% decrease in new cases and 26% decrease in the deaths caused by Tb (Dye et. al., 
1998). 
Unfortunately the development of drug resistance to the first line drugs (FLDs) such 
as isoniazid, rifampin, streptomycin caused concern due to the development of a new 
drug resistant strain, MDR-TB (Multi Drug Resistant Tuberculosis) (Blanchard, 
1996). Among many things such as lack of knowledge about antitubercular drugs, 
improper prescription of drugs, non-standardized regimen and poor patient adherence 
the control of tuberculosis being the major reasons for this strain to develop, which 
leas to increase in cases of MDR TB with poor therapeutic outcomes. The WHO to 
deal with treatment of MDR TB established the Green Light Committee for proper 
use of second line drugs (SLDs) and prevents further drug resistance (Shah et. al., 
2007). The SLDs were administered as per requirement after correctly differentiating 
patients with primary resistance (those patients who had not been treated before but 
were resistant to FLDs) and patients with acquired resistance (who acquired resistance 
due to improper FLD regimen). It was clearly observed that patients with acquired 
resistance were higher than ones with primary resistance (Cohn et. al., 1997). 
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Unfortunately, cases with resistance to SLDs also started developing, leading to a new 
strain of XDR TB (Extremely drug resistant tuberculosis). This strain is defined as 
bacilli resistant to a minimum 3 SLDs as MDR is managed with 4 or more SLDs. 
Inadequate monitoring of MDR TB, using too few drugs for treatment, poor quality of 
SLDs, failing adherence to drug regimen could have been the causes for resistance 
(Shah et. al., 2007; Munro et. al., 2007). The mechanism of acquire drug resistance is 
not very clearly understood. But there are several studies, which have shown 
resistance related to chromosomal alterations (S T Cole, 1994) mainly involving 
mutations in specific genes related to resistance of drugs (Fenner et. al., 2012; 
Motiwala et. al., 2010). It has also been said that the bacillus gains these mutations 
sequentially, one drug at a time and may also be able to resist destruction by drugs 
due to induction of drug efflux pumps (Srivastava et. al., 2010). Drug resistance has 
also been accredited to horizontal transfer of mobile elements such as plasmids, 
transposons, integrons that impart resistance to the bacillus (Da Silva and Palomino, 
2011). 
1.5	  Cell	  wall	  
 
The mycobacterial cell wall is made up of two segments, the upper and lower 
segments. The lower segment of the cell wall is made up of peptidoglycan covering 
the cell membrane, which is then followed by arabinogalactan, which is bound by 
mycolic acids. These mycolic acids have long chain meromycolates and short α- 
chains. The cell wall core is therefore called as the mycolyl arabinogalactan 
peptidoglycan complex (mAGP complex) as shown in Fig.20. The upper segment of 
the cell wall is scattered with free lipids intermingled with cell wall proteins, 
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phosphotidyl inositol manosides (PIMs), pthiocerol-containing lipids, lipomannan 
(LM) and lipoarabinomannan (LAM) and are known to assist in host immune evasion 
(Brennan, 2003). Lipids such as trehalose dimycolate/monomycolate (TDM/TMM), 
pthiocerol dimycocerosate (PDIM) and sulfolipids (SL) are main virulence lipids.  
There are many cell wall associated proteins such as lpqH (19kDa), pstS1 (38kDa), 
tlr2 agonists etc. which play a role in regulating the action of macrophages and 
dendritic cells along with secreted proteins which act as antigens and can act as drug 
targets and biomarkers for diagnostics (Wolfe et. al., 2010). 
 
Figure 20: The cell wall components of Mycobacterium tuberculosis. (Abdallah et. 
al., 2007). 
Mycobacterium mycolic acids (MAs) play an important role in growth and survival of 
the bacillus both in vivo and in vitro. Its different structural properties regulate the 
manipulation of the host immune system and virulence of the bacillus. The MAs 
bound to the peptidoglycan cause the inflammatory activation of dendritic cell and 
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macrophages by interaction via TLR2 and TLR4 receptors. The free mycolates are 
involved in maintaining the structure of the granuloma, which helps in maintaining 
the optimal survival condition for the bacillus (Verschoor et. al., 2012). It has also 
been seen that the mycolic acids stimulate production of antibodies in humans, which 
can potentially be used for diagnostic and therapeutic purposes. The permeability 
barrier of the cells produced by the thick waxy cell wall is the major cause of drug 
resistance in mycobacterium along with other factors such as efflux pumps, which 
help it to gain resistance against antibiotics. (Niederweis et. al., 2009; Kolattukudy et. 
al., 1997).  
Bacteria from the suborder Corynebacterineae which include the M. tuberculosis 
complex (pathogenic) and the M. smegmatis (non pathogenic) along with C. 
glutamicum have various liposaccaharides such as LAM and related glycoconjugates 
varying in each species minutely (Tam and Lowary, 2009) The biogenesis of the cell 
wall is a complex process involving a series of interconnecting cycles and enzymes, 
(Acharya and Goldman, 1970) but it is also seen that genes involved in this are 
essential to the bacteria (Mishra et. al., 2011). Therefore, the understanding of the 
enzymatic machinery and cell wall synthesis process could lead to novel drug targets 
and inhibitors to enzymes involved can act as drugs (Mishra et. al., 2011). 
1.6	  Antibiotics	  for	  tuberculosis	  treatment	  and	  resistance 	  
	  
The following table describes the list of antibiotics already in use with specific 
inhibitory concentrations used for inhibiting the growth of Mycobacterium. It 
mentions the genes whose products are affected by the activity of the antibiotic. 
Further detailed discussion about the same would be done in this section.  
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Table 2: Representing the antibiotics used for tuberculosis, with the MIC values, gene 




Figure 21: The chemical structure of Isoniazid 
It is an antibiotic containing a pyridine ring and a hydrazide group (Fig.21) both of 
which are important components for its activity against Mycobacterium. Opposite to 
its simple structure its mechanism of actions is considered quite complex 
(Middlebrook et. al., 1953). It interferes with the synthesis of essential mycolic acids 
by inhibiting NADH-dependent enoyl ACP reductase that is encoded by a gene ihnA 
been recognized as an important factor in the natural resistance
of mycobacteria against antibiotics such as tetracycline, fluoro-
quinolones and aminoglycosides, among others.11
In Mycobacterium smegmatis, it has been shown that mutants
lacking the major porin MspA had an increased MIC of the
b-lactam antibiotics ampicillin and cefaloridine. Deletion of the
mspA gene also increased the MIC of vancomycin, erythromycin
and rifampicin by 2- to 10-fold.12 Using the same model organism,
it was shown that deletion of the porins MspA and MspC increased
the resistance to b-lactam antibiotics without affecting its
b-lactamase activity, which remained unchanged. This study
also showed that hydrophilic fluoroquinolones such as norfloxacin,
but also chloramphenicol, diffuse through porins in mycobac-
teria.13 b-lactam antibiotics bind and inhibit the activities of
penicillin-binding proteins involved in cell wall biosynthesis, but
mycobacteria possess b-lactamase enzymes that degrade these
drugs. This is the main mechanism conferring resistance to
b-lactam antibiotics. In M. tuberculosis, b-lactamase activity is
encoded by blaC and blaS. The use of b-lactamase-resistant
b-lactam antibiotics or b-lactam in combination with
b-lactamase inhibitors has been shown to be effective in killing
M. tuberculosis.14 Recent studies have shown that in M. tuberculosis,
Rv1698 can have the same function as MspA in contributing to
intrinsic resistance to hydrophilic compounds.15 Moreover, bioin-
formatics analysis has identified both Rv1698 and Rv1973 as
being mycobacterial outer membrane proteins (OMPs) with a
possible role in the intrinsic resistance to some antibiotics.16
But not only permeability barriers or b-lactamases are respon-
sible for the intrinsic resistance to antibiotics in mycobacteria.
Physiological adaptations occurring within the host can also be
responsible for antibiotic tolerance.17 Finally, in M. tuberculosis,
whiB7 is an MDR determinant whose deletion produces a
multidrug-susceptible phenotype, suggesting its role as an ances-
tral MDR determinant.18
Intrinsic resistance is thus important since it limits the
number of drugs available for treatment and favours the emer-
gence of strains with a high level of drug resistance.
Consequently, drugs inhibiting these mechanisms would enable
potential new use against M. tuberculosis of many antibiotics
that are already available but have not been used before in the
treatment of TB.19,20
Acquired drug resistance
Unlike the situation in other bacteria where acquired drug resist-
ance is generally mediated through horizontal transfer by mobile
genetic elements, such as plasmids, transposons or integrons, in
M. tuberculosis, acquired drug resistance is caused mainly by
spontaneous mutations in chromosomal genes, producing the
selection of resistant strains during sub-optimal drug therapy.21
Although no single pleiotropic mutation has been found to
cause an MDR phenotype in M. tuberculosis, a possible complex
association between classical mutations associated with resist-
ance to one drug could be related to initial steps in the resistance
to other drugs.22
In prokaryotes, spontaneous mutations occur at a low rate of
0.0033 per replication. The mutation rate per bp is inversely pro-
portional to the genome size. Previous studies have shown that
the rate of mutation depends on the nature of the drug selection,
but for most of the main anti-TB drugs, this occurs at a rate of 1029
mutations per cell division. This is the main reason why anti-TB
drugs are given as a combination, as the risk of a mutant contain-
ing two resistance mutations is ,10218.23
In the following sections we will present an updated review
on individual anti-TB drugs, including new proposed anti-TB anti-
biotics, and their molecular mechanisms of drug resistance. In
addition, see Table 1. It is noteworthy that most of the drugs
currently in use to treat TB are specific for M. tuberculosis.
Isoniazid
Isoniazid is one of the main drugs for the treatment of TB. It has
a simple structure containing a pyridine ring and a hydrazide
group, with both components being essential for the high activity
Table 1. Drugs, MICs and mechanisms of drug resistance
Drug MIC (mg/L) Gene Role of gene product Reference
Isoniazid 0.02–0.2 (7H9/7H10) katG catalase/peroxidase 26
inhA enoyl reductase 35
ahpC alkyl hydroperoxide reductase 38
Rifampicin 0.05–0.1 (7H9/7H10) rpoB b-subunit of RNA polymerase 54
Pyrazinimide 16–50 (LJ) pncA PZase 66
Streptomycin 2–8 (7H9/7H10) rpsL S12 ribosomal protein 78
rrs 16S rRNA 78
gidB 7-methylguanosine methyltransferase 81
Ethambutol 1–5 (7H9/7H10) embB arabinosyl transferase 84
Fluoroquinolones 0.5–2.0 (7H9/7H10) gyrA/gyrB DNA gyrase 99
Kanamycin/amikacin 2–4 (7H9/7H10) rrs 16S rRNA 112
Capreomycin/viomycin 2–4 tlyA rRNA methyltransferase 116
Ethionamide 10 (7H11) inhA enoyl reductase 30
p-amino salicylic acid 0.5 (LJ) thyA thymidylate synthase A 127
PA-824 and OPC-67683 0.03 (7H9/7H10) Rv3547 hypothetical 16.4 kDa 147
TMC207 0.03 (7H9/7H10) atpE ATP synthase 151
Review
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in Mycobacterium (Rawat et. al., 2003). Strains that developed resistance against 
isoniazid have shown to have mutations within inhA and another gene called katG. 
(Silva et. al., 2003; Ramaswamy et. al., 2003). The mutation within katG known as 
S315T is a second step mutation caused due to inappropriate chemotherapy and is 
more frequently seen in MDR rather than isoniazid mono-resistant strains (Hazbon et. 
al., 2006). Mutation in inhA has been known to cause resistance in second line drugs 
as well due to the same mechanism of action (Banerjee et. al., 1994). Another gene 
called ndh when mutated decreases the activity of NADH dehydrogenase and 





Figure 22: The chemical structure of Rifampicin 
Rifampicin is a lipophilic ansamycin (Fig. 22) with antimicrobial activity (Rattan et. 
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al., 1998). It binds to the β- subunit of RNA polymerase and inhibits the elongation of 
messenger RNA (Blanchard, 1996). It acts against both active and non-growing 
bacilli. Resistance against rifampicin is generated by mutation with the rpoB gene in a 
region from 507-533 codon, called the rifampicin resistance-decreasing region 
(RRDR) (Ramaswamy et. al., 1998). Resistance to rifampicin has shown the bacillus 




Figure 23: The chemical structure of Pyrazinamide 
It is a structural analogue to nictoniamide (Fig. 23). It is a pro-drug, which is 
converted into its active form pyrazinoic acid via the enzyme pyrazinamidase or 
nicotinamidase (Pzase) (Konno et. al., 1967) encoded by pncA (Scorpio et. al., 1996).  
The active form of the drug disrupts the bacterial membrane energetics and inhibits 
membrane transport. The drug is known to be able to inhibit semi-dormant bacteria 
living within acidic environment, which it does by disrupting the bacterial membrane 
having a low membrane potential (Zhang et. al., 2003; Mitchison et. al., 1985). It has 
also been suggested that pyrazinoic acid and n-propyl esters inhibit fatty acid synthase 
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type- I in replicating bacilli (Zimhony et. al., 2007). Resistance against pyrazinamide 
is due to mutations that occur in the 561bp promoter open reading frame region in 




Figure 24: The chemical structure of Streptomycin 
Streptomycin, an aminocyclitol glycoside antibiotic was the first antibiotic used for 
tuberculosis isolated from Streptomyces griseus (Fig 24). It inhibits mycobacterial 
growth by binding to the 16SrRNA (Moazed et. al., 1987). Resistant strains emerged 
after its initial use as a monotherapy against tuberculosis (Crofton et. al., 1948). 
Genetic resistance is responsible due to mutations in rrs and rpsl genes, which alter 
the streptomycin-binding site. Such mutations are observed in around 50% of strains 
(Gillespie et. al., 2002). The majority of point mutations are found in rpsl, most 
common being K43R. But their are resistant strains, which have been found 
containing no mutations in either of the two genes that suggest that there are other 
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Figure 25: The chemical structure of Ethambutol 
Ethambutol, having the chemical name (S, S) – 2,2’ – (ethylenediimino) di- 1- 
butanol (Fig. 25) has been used as a first line drug in combination with isoniazid, 
streptomycin, rifampin and pyrazinamide to treat tuberculosis (Sreevatsan et. al., 
1997). The mode of action of the drug was said to be by inhibition of cell wall 
biosynthesis, mainly by two possible mechanisms of either direct inhibition of 
transfer of mycolic acid to the cell wall or by inhibiting synthesis of acceptors of 
mycolic acid (Takayama et. al., 1979). In M. smegmatis the genes whose products 
were targeted by ethambutol were found to be in an operon, containing three genes 
embA, embB and embC (Sreevatsan et. al., 1997). Recent development of resistance 
against antibiotics and study on mechanisms for antibiotic resistance lead to the 
discovery that mutations in specific codons in genes which are targeted by ethambutol 
cause resistance (Safi et. al., 2008). Mutations in codon 306 in embB gene (Telenti et. 
al., 1997) have been seen in most resistant strains and have been known to develop a 
resistance for other drugs mainly isoniazid and rifampin evolving into MDR (Safi et. 
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al., 2008).  
1.6.6	  p-­‐Amino	  Salicylic	  acid	  	  
 
 
Figure 26: The chemical structure of p- Amino Salicylic acid 
4- amino – 2- hydroxyl benzoic acid also known as p- amino salicylic acid (Fig. 26), 
was confirmed as a potent antitubercular drug against 12 virulent strains of human 
tubercule bacilli a few being resistant to streptomycin (James A. O’ Connor, 1948). In 
the beginning the drug showed poor patient compliance due to gastro intestinal 
toxicity but after the development of a new formulation and a need for new antibiotics 
due to and increase in MDR cases the use of it as an antitubercular antibiotic was 
back in place. Due to its structural similarity to sulphonamides it was thought to be 
competing with PABA (p- amino benzoic acid) for dihydropteroate synthase (DHPS) 
in the folate synthesis cycle (Rengarajan et. al., 2004). But when further investigated 
it was seen that PAS was a prodrug activated via a product from the gene thyA coding 
for thymidylate synthase A, an important enzyme in thymine synthesis (Rengarajan 
et. al., 2004, Leung et. al., 2010). PAS resistance is associated with mutations in the 
thyA gene, where in most common is the threonine to alanine conversion on the 202 
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position (Leung et. al., 2010).  Although this fact was challenged to a study proving 
the mutation to be a marker for Latin American Mediterranean (LAM) lineage of M. 





Figure 27: The chemical structure of Ethionamide 
Ethionamide (Fig. 27) has a structure similar to isoniazid and is known to have a 
similar mode of action by inhibiting the mycolic acid biosynthesis. Studies show that 
both isoniazid and ethionamide target the gene inhA responsible for the synthesis of 
enoyl acyl ACP reductase in Mycobacterium (Wang et. al., 2007). Mutation in the 
S94 allele of the inhA gene caused a five-fold increase in resistance against isoniazid 
and ethionamide in M. tuberculosis and M. bovis BCG (Vilcheze et. al., 2006). 
Although it is proven that the target of both antibiotics might be the same the mode of 
activation for both is different. Ethionamide like isoniazid is a prodrug which is 
activated by the product of the gene ethA (Wang et. al., 2007), responsible for 
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synthesis of monoxygenase (Leung et. al., 2010) which activates the ethionamide by 
forming an adduct with NAD and inhibiting inhA (Vilcheze et. al., 2008). 9 different 
types of mutations have been identified in ethA gene , which increases resistance to 
ethionamide by decreasing activation of the antibiotic (Leung et. al., 2010). Another 
gene, which is a target of isoniazid, katG has been associated with ethionamide 
resistance. Mutation in the katG gene has been said to provide a favorable 
environment for the development of ethionamide resistance. (Hazbon et. al., 2006). 
Some new genes such as mshA involved in mycothiol biosynthesis (Vilcheze et. al., 
2008) and ndh producing type II NADH dehydrogenase (Vilcheze et. al., 2005) have 
been implicated in being involved in ethionamide function; as mutations in these 
genes have conferred resistance to Mycobacterium strains against both isoniazid and 
ethionamide, 
The above mentioned antibiotic are used as treatment for tuberculosis but due to 
increases in strains of resistant Mycobacterium it is imperative to look for drugs with 
better efficacy and targets which will help improve the drug regimen for treatment of 
afflicted patients. 
1.7	  High	  Throughput	  Screening	  (HTS)	  for	  novel	  compounds	  with	  
anti-­‐tubercular	  activity	  	  
 
Screening of antibiotics was previously performed via various cell-based assays, 
which were manually curated and handled individually. With the development of 
assay plates or microwell plates containing wells ranging for 96 to 384 wells in a 
single rectangular plate; the process of screening was made simpler and quicker. But 
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with rapid increase in the number of synthesized antibiotics and compound libraries it 
became imperative to automate liquid handling systems and improvise assays to give 
quicker and accurate results with lesser discrepancies. The drawbacks of optical 
density based assays in terms of variation in cell number and growth rate lead to 
attempts at speeding up the process of drug discovery by using assays using redox 
dyes (alamar blue), tetrazolium for Mycobacterium to detect compound or antibiotic 
activity against the microbe (Singh et. al., 2010). A compound library from NIH; 
SMR (small molecule repository) was screened using the Alamar blue end point assay 
to screen 215,110 compounds resulting in “hits” comprising of compounds ranging 
from substituted pyrimidines and quinolones to thiadiazoles and pyrazoles. (Maddry 
et. al., 2009). Although, such assays seem to be depending on continuing C.F.U and 
long incubations with the dye as a main assessment technique which might lead to 
alteration of the metabolic and physiological state of the bacillus (Singh et. al., 2010). 
Even though whole cell screening assays have lead to new pathways and enzymes 
encouraging drug discovery (Sala and Hartkoorn, 2011), direct screening of M. 
tuberculosis is a challenging task as it involves the use of a BSL-3 containment with 
the HTS equipment. This has lead to the use of other Mycobacterial species as model 
organisms to be used for screening out drugs. Around 20,000 molecules from the 
Broad Institute were screened to get novel inhibitors targeting DprE1 (enzyme for cell 
wall synthesis) and MmpL3 (mycobacterial cell membrane protein large 3), which is 
an exporter of newly synthesized cell wall mycolic acids using GFP fluorescence as 
reporters (Stanley et. al., 2012). HTS has also been used to validate inhibitors against 
specific targets such as lspD which is an enzyme used in the pathway for synthesizing 
isopentenyl diphosphate (IPP) and its isomer dimethylallyl diphosphate (DMAPP) 
which play a role in the electron transport chain (Gao et. al., 2012). Specific assays 
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against M. tb dihydrofolate reductase (important for folate pathway) involving the use 
of fluorescent dye resazurin, which measures the metabolic state of the cells was 
designed to screen out 32,000 synthetic and natural product derived compounds 
(Kumar et. al., 2012) while a dual selection assay against 1-deoxy-D-xylulose-5-
phosphate synthase (DxS) or 1-deoxy-D-xylulose-5-phosphate reductoisomerase 
(DxR) was designed using an increase in NADH concentration to detect DxR 
inhibitors which could also screen out compounds against DxS simultaneously 
(Humnabadkar et. al.,2011). Novel HTS assays have been designed against non-
replicating bacilli having antimicrobial tolerance by a low oxygen recovery assay 
using a plasmid containing acetamide promoter driving a bacterial luciferase gene 
adapted to low oxygen conditions. It was seen that agents against cell wall were 
inactive against NRP but have shown promise against other cellular targets (Cho et. 
al., 2007). An assay against glutamine synthetase was designed, optimized and 
standardized to all conditions such as temperature, DMSO concentration and culture 
volume related to the assay to get a robust assay to screen 18,000 small molecules 
(Singh et. al., 2005). An automated confocal based fluorescence microscopy HTS 
screening of 57,000 small molecules lead to 135 potent compounds such as 
dinitrobenzamide derivatives against the synthesis of LAM and AG synthesis 
including activity against XDR. (Christophe et. al., 2009)  
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Figure 28: A flowchart representing drug discovery strategies describing the drug 
development from drug to target and from target to drug. The two strategies overlap at 
a level for in vivo studies. HTS – High throughput screening. (Sala and Hartkoorn, 
2011) 
There are two major ways in which screening of drugs seems to be carried out, either 
assays are designed to be specific against at target leading to inhibitors of specific 
enzymes, pathways or molecules whereas a more generalized approach involves cell 
based assays to reflect any inhibitory compounds which can be studied further for 
their mode of actions on the bacteria. The flowchart above summarizes the various 
strategies currently in place for drug discovery and development of antitubercular 
drugs using high throughput screening (Sala and Hartkoorn, 2011) (Fig. 28).  
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2.	  RATIONALE	  OF	  STUDY	  
 
Over the years the global scenario of tuberculosis has changed leading to worldwide 
emergency declared by the WHO in 1993. The control of which has been highly 
deterred due to the emergence of high number of drug resistant strains (Da silva and 
Palomino, 2011). The need of the hour therefore, points towards newer drug 
development and discoveries with increased speed and resilience. HTS of drugs and 
synthetic compounds has proved to be a useful and speedy platform for drug 
development. Although, a good assay for HTS should have a combination of a micro 
plate format, a low cost such as of reporter assays using fluorescent proteins or cell 
density measurement and redox dye assays, which use electron transport as an 
indicator (such as ATP, NADP, FAD conversions) with easy kinetic monitoring of the 
BACTEC system. (Collins et. al., 1998). A comparative analysis of BACTEC 460 
assay and the Alamar Blue assay lead to the conclusion that as opposed to the 
expensive, cumbersome and radioactive assay the alamar blue assay is a reliable, non- 
radioactive and cheap assay for HTS (Collins and Franzblau, 1997).  The use of redox 
dyes as such does lead to questionable physiological changes that the bacteria might 
go through during incubation (Singh et. al., 2010) and also its difficult nature for 
kinetic or real time monitoring of antibiotic activity (Collins et. al., 1998). 
Fluorescence assays can prove to be better kinetic as well as end point assays as seen 
from many drug screens utilizing fluorescent dyes such as resazurin (Kumar et. al., 
2012) and green fluorescence proteins (Christophe et. al.2009).  
Therefore an optimized and validated assay utilizing fluorescent proteins produced by 
	   87	  
the bacillus could give real time results of antitubercular activity as well as decreasing 
the risk of interaction with other dyes and reagents at the same time, which would not 
influence the physiology of the bacillus.   
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3 AIM AND OBJECTIVES	  
 
3.1	   Aim: Development of a phenotypic HTS assay to identify novel molecules 
that inhibit Mycobacteria. 
 
3.2	  Objectives:	  
1. To create genetically modified strains of M. smegmatis expressing fluorescent 
proteins for assay development. 
 
2. To optimize conditions such as media, cell concentration, time range, 
antibiotic concentration etc. required to get a reliable and repetitive assay. 
 
3. To screen compounds and drugs from libraries against the Mycobacterium 
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4. MATERIALS AND METHODS 
4.1	  Antibiotic	  stocks	  
 
Antibiotics were prepared as stock solutions at a higher concentration to be diluted to 
different working concentrations as per requirement.  
	  
4.1.1	  Standard	  antibiotics	  
 
Requirements: For 10mM stocks (5mL) – Isoniazid – 6.85mg, Ethambutol – 13.86mg, 
Streptomycin – 36.44mg, Pyrazinamide – 6.16mg, Rifampicin – 41.15mg 
For 100mg/mL (5mL) – All antibiotics required at 500mg. 
Procedure: The standard antibiotics (Isoniazid, Ethambutol, Rifampicin, 
Pyrazinamide used were prepared as stocks in DMSO, while Streptomycin was 
prepared in sterile water as solutions at concentrations of 10mM and 100mg/mL. The 
antibiotics were filter sterilized using a 0.2µm pore size filter.  
	  
4.1.2	  FDA	  Drugs	  
 
Requirements: For 10mM stocks (250µL) – Tamoxifen citrate – 1.4091mg, 
Meclocycline sulfosalicylate salt – 1.737mg, Clomiphene citrate salt – 1.4952mg, 
GBR 12909 dihydrochloride – 1.308mg, Sulocitidil – 0.8439mg, Fendiline 
hydrochloride – 0.8797mg, R- (-)- Apomorphine hydrochloride hemihydrate – 
0.782mg 
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Procedure: The FDA drugs (Tamoxifen citrate, Meclocylcine sulfosalicylate salt, 
Clomiphene citrate salt, GBR 12909 dihydrochloride, Sulocitidil, Fendiline 
hydrochloride, R- (-)- Apomorphine hydrochloride hemihydrate) selected after the 
screen were prepared as stocks at concentrations of 10mM in DMSO. 
	  
4.1.3	  Stock	  antibiotics	  for	  screening	  transformed	  M.	  smegmatis	  	  
 
Requirements: For Kanamycin stocks 10mL – 500mg; Hygromycin stock (available) 
Procedure: Kanamycin was prepared as a stock solution of 50mg/mL in water and 
was filter sterilized using a 0.2µm pore size filter. The working concentration of 
Kanamycin was 10µg/mL. 
Hygromycin was available as a stock solution in PBS at a concentration of 50mg/mL 
and was used at a working concentration of 20 µg/mL 
4.2	  Culture	  media	  
 
Various culture medias were used to grow Mycobacterium smegmatis to ensure 
optimum growth conditions for a reliable assay. 
4.2.2	  Tryptic	  Soy	  Broth	  (TSB)	  
 
The TSB media was prepared by dissolving 7g of TSB in 250mL of distilled water. 
The solution was then autoclaved at 121°C for 20 minutes. 
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4.2.3	  Tryptic	  Soy	  Agar	  (TSA)	  
 
The TSB agar was prepared by dissolving 7g of TSB, 3g of Agar in 250mL of 
distilled water. The solution was then autoclaved at 121°C for 20 minutes. The 
solution was brought to around 50-60 °C then poured into sterile petri plates and 
allowed to solidify. 
	  
4.2.4	  Tripticase	  Soy	  Broth	  
 
The TSB media was prepared by dissolving 7.5 g of Tripticase SB in 250mL of 
distilled water. The solution was then autoclaved at 121°C for 20 minutes. 
	  
4.2.5	  Middlebrook	  7H9	  Broth	  
 
The 7H9 broth was prepared by dissolving 1.31g of Middlebrooke 7H9 in 250mL of 
distilled water. To which 556µL of Glycerol was added. The solution was then 
autoclaved at 121°C for 20 minutes. 
 
 
4.2.6	  Tween-­‐	  80	  (10%)	  
	  
Polysorbate 80 or Tween 80 is a hydrophilic non-ionic surfactant and emulsifier used 
in the culturing of Mycobacterium sps., to avoid clumping of cells and get an even 
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suspension of cells. A 10% tween-80 solution was prepared by dilution in distilled 
water followed by filter sterilization using a 0.2µm pore size filter. 
	  
4.3	  Culturing	  bacterial	  cells	  
	  
4.3.1	  Wild	  type	  M.	  smegmatis	  (mc2	  155)	  
	  
Small-scale cultures were setup in 20mL culture bottles with 10mL TSB, 50µL 
Tween 80 (10%). A loopful of colony from a streaked plate was inoculated in the 
medium and incubated at 37°C, 150rpm, 48hrs.  
Scale up cultures were then setup using the small scale culture batch as inoculum with 
100mL TSB, 50 µL Tween 80 (10%) and 2mL of inoculum at 37°C, 150rpm, 
overnight. 
 
4.3.2	  M.	  smegmatis	  (pMind_gfp)	  
 
The plasmid used to transform was pMIND_gfp, which was a plasmid whose gfp 
expression was regulated by the conditional presence of tetracycline. It was derived 
from a plasmid containing the luxAB gene encoding the luciferase enzyme. The 
plasmid has a gfp codon alongwith an antibiotic marker for kanamycin. The 
expression of gfp is controlled by a tetracycline stimulation (Fig. 29) (Blokpoel et. al., 
2005). 
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Fig 29: pMind_gfp plasmid with a Kanamycin resistance gene and the tetracycline 
gene for controlled production of GFP in the cell (Blokpoel et. al.,2005) 
Small-scale cultures were setup in 20mL culture bottles with 10mL TSB, 50µL 
Tween 80 (10%), 10µL Kanamycin (50mg/mL). A loopful of colony from a streaked 
plate was inoculated in the medium and incubated at 37°C, 150rpm, 48hrs.  
Scale up cultures were then setup using the small scale culture batch as inoculum with 
100mL TSB, 50 µL Tween 80 (10%), 100µL Kanamycin (50mg/mL) and 2mL of 
inoculum at 37°C, 150rpm, overnight. 
 
4.3.4	  M.	  smegmatis	  (pSMT3_egfp)	  
 
The plasmid used to transform the strain was pSMT3_egfp, which has a shuttle vector 
pSMT3 for Mycobacterium with an hsp60 promoter (Hayward et. al., 1999). It has 
restrictions sites for BamH1 and Hind III digestion sites. It has been cloned with an 
enhanced GFP codon and has an antibiotic marker for hygromycin. The GFP 
expression is independent of the hygromycin induction (Fig.30) (Humphreys et. al., 
2006; Abdallah et. al., 2006). 
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Fig 30 : The pSMT3_sgfp plasmid with a Mycobacteria shuttle vector pSMT3; 
hygromycin marker, and enhanced GFP codon with a hsp60 promoter (Humphreys et. 
al., 2006) 
Small-scale cultures were setup in 20mL culture bottles with 10mL TSB, 50µL 
Tween 80 (10%), 20µL Hygromycin (50mg/mL). A loopful of colony from a streaked 
plate was inoculated in the medium at incubated at 37°C, 150rpm, 48hrs.  
Scale up cultures were then setup using the small scale culture batch as inoculum with 
100mL TSB, 50 µL Tween 80 (10%), 200µL Hygromycin (50mg/mL) and 2mL of 
inoculum at 37°C, 150rpm, overnight. 
 
 
4.4	  Transformation	  of	  M.	  smegmatis	  wild	  type	  strain(mc2	  155)	  	  
to	  GFP	  strains	  	  
 
To produce genetically modified strains of M. smegmatis expressing green 
fluorescence protein for HTS screening of drugs, the plasmids with a GFP marker had 
to be electroporated into wild type M. smegmatis strains. The procedure involved 
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producing electrocompetent cells to electroporate the said plasmids and then 
screening out the transformed cells. 
	  
4.4.1	  Preparation	  of	  electrocompetent	  cells	  	  
 
Requirements: 10% sterile glycerol, Ice, wild type M. smegmatis (100mL, O.D600 -
0.8) 
Procedure: 100mL large-scale culture of wild type M.smegmatis was cultured 
overnight. The culture was then incubated on ice for 1.5hrs after which it was 
centrifuged at 3000g, 10 minutes. The cells were washed with ice cold 10% glycerol 3 
times reducing the volume each time. A 100 mL culture after centrifugation was 
washed with 25mL; 10mL and 5mL of 10% ice cold glycerol consecutively. The 
electrocompetent cells were then aliquoted and stored at -80°C after flash freezing 
with liquid nitrogen (-196°C). 
 
4.4.2	  Electroporation	  of	  electrocopetent	  cells	  with	  GFP	  gene	  containing	  	  	  	  
plasmids	  
 
Requirements: Electrocompetent cells, electroporation cuvets (0.2cm gap electrodes), 
electroporation apparatus with pulse controller, Plasmid DNA in solution (approx. 
concentration 0.2-1mg/mL), TSB, Ice. 
Procedure: 5µL of plasmid DNA was added to 200 µL of electrocompetent cells and 
kept in ice for 10minutes. The cells were then transferred into an ice-cold sterile 
electroporation cuvet ensuring that there are no bubbles in the culture in the cuvet. 
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The cuvet was then placed in the electroporation chamber and subjected to a single 
pulse of 1.8kV with pulse controller resistance set at 1000Ω resistance. The cuvet was 
pot back in ice for 10minute. The suspension was transferred to a sterile 
microcentrifuge tube (1.5mL) and 5mL of TSB was added to it. The cells were then 
incubated at 37°C for 4hrs. The cells were then plated on agar plates containing 
selective antibiotic for each plasmid and incubated at 37°C for 3-7 days till colonies 
appear. 
Plasmids transformed into wild type M. smegmatis were pMind_gfp (Kanamycin 
resistant marker) and pSMT3_egfp (hygromycin resistant marker). 
	  4.4.3	  Glycerol	  Stocks	  
 
Glycerol stocks were prepared using fresh cultures with an O.D600 of 0.5-0.6. The 
stocks were prepared by adding 1mL of bacterial culture, 357 µL of sterile glycerol 
(70%) so that the final concentration of glycerol reaches 25% in the culture. The 
cryovials were then flash frozen using liquid nitrogen (-196°C) and then stored at -
80°C. 
4.5	  Assay	  Optimization	  
 
The assay runs started with growth curve analysis using standard antibiotics used for 
M. tuberculosis. The runs were carried out on wild type M. smegmatis (positive 
control) and the transformed M. smegmatis strains. The assays run were tweaked and 
corrected from changing media, maintaining optimal DMSO concentrations, deciding 
optimal time range and finalizing the GFP strain to achieve the best possible assay 
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conditions suitable to run a compound or drug screen. The drugs were screened 
through HTS by using the automated MICROLAB® STAR Liquid Handling 
Workstations by Hamilton. Plate preparation was manual or automated depending on 
the assay specifications. Assay plate creation methods were used to create 
intermediate plates, plates for assays and setup up read time intervals.  
4.5.1	  Assay	  Run	  1	  
 
The assay setup was done beginning with validating any innate resistance in the M. 
smegmatis (mc2155) strain against the antibiotics used in screening the transformed 
bacterial strains. The assay plates were setup with varying conditions to rule out 
possible loopholes for error. The assay plate setup for the preliminary run with 
transformed M. smegamtis was done to check the effectiveness of strains as screening 
indicators. For M. smegmatis (pMind_gfp) conditional presence of tetracycline was 
required to induce gfp production while for M. smegmatis (pSMT3_egfp) gfp was 
constitutively produced. In order to use the minimum concentration of tetracycline to 
rule out its effect on bacterial growth during final screening various concentrations of 
tetracycline were tested to observe a good level of fluorescence. 
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Figure 31: The above assay plates depicts the setup for a positive control plate with 
wild type M. smegamtis (mc2 155) in the presence and absence of both hygromycin 
and kanamycin; to check for innate resistance. 
 
Figure 32: The above assay plates depict the setup for M. smegmatis (pSMT3_egfp) 
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Figure 33: The above assay plates depicts the setup for M. smegmatis (mc2155) and 
M. smegmatis (pMind_gfp) with varying conditions; presence of Kanamycin and 
tetracycline. Two plates were setup in the same manner with different strains to have 
half of the plate as a duplicate for the experimental validation. 
4.5.2	  Assay	  Run	  2	  
 
After observation of the fact that there was no innate resistance of M. smegmatis 
(mc2155) against the antibiotics kanamycin and hygromycin another assay was done 
to get appropriate fluorescence window to get a reasonable cut off value. This was 
done by varying the cell concentration in two ways by diluting it in an equal ratio 
with the medium and by serially diluting the cells to 10 folds. Observing the 
fluorescence levels in the presence of various tetracycline concentrations, we decided 
on narrowing down the concentrations to three main concentrations that were 
5.0ng/mL, 10.0ng/mL and 15.0ng/mL. Also to check for any background fluorescence 
observed media controls were maintained both with and without tetracycline. Cells 
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media was changed from TSB to 7H9 as TSB and other similar substitute medias such 
as Tripticase SB showed high level of internal fluorescence causing low assay quality 
and high error. 
 
 
Figure 34:  The above assay plates depicts the setup for M. smegmatis (mc2155), M. 
smegmatis (pSMB_egfp) and M. smegmatis (pMind_gfp) with varying conditions; 
presence of Kanamycin and tetracycline. All conditions were performed in duplicate 
rows to maintain assay validation. 
4.5.3	  Assay	  Run	  3	  
 
Observing background fluorescence from tetracycline and irregular fluorescence 
values; we finally selected M. smegmatis (pSMT3_egfp) as an indicative strain to do 
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gave better values rather than serially diluted cells. Therefore, two plates with 2 fold 
serially diluted antibiotics (10mM stock concentrations) were prepared with two 
strains of M. smegmatis (mc2155 and pSMT3_egfp) alongwith media controls. The 




Figure 35:  The above assay plates depict the setup for M. smegmatis (mc2155) and M. 
smegmatis (pSMT3_egfp) with serially diluted standard antibiotics by 2 folds. All 
conditions were performed in duplicate rows to maintain assay validation. INZ – 
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  4.5.4	  Assay	  Run	  4	  
 
Since the antibiotics were prepared in DMSO, which has shown to inhibit M. 
smegmatis growth DMSO controls was run alongwith the next assay. Also the number 
of antibiotic dilutions in the previous assay did not show much variation in growth 
curve as based on antibiotic concentration; therefore the number of dilutions were 
increased for the next assay run. Two plates were individually setup to run an assay 
on all four antibiotics. 
 
Figure 36:  The above assay plates depict the setup for M. smegmatis (mc2155) and M. 
smegmatis (pSMT3_egfp) with serially diluted standard antibiotics by 2 folds and 
DMSO controls alongwith media controls. All conditions were performed in duplicate 
rows to maintain assay validation. INZ – Isoniazid, PYZ – Pyrazinamide, EMB – 



















	   103	  
	  4.5.5	  Assay	  Run	  5	  
 
A repeat assay from the above run with slight variation in terms of checking different 
DMSO concentrations and its effect on M. smegmatis both wild type and 
pSMT3_egfp-containing strains was performed. The DMSO concentrations were 





Figure 37:  The above assay plates depict the setup for M. smegmatis (mc2155) and M. 
smegmatis (pSMT3_egfp) with serially diluted standard antibiotics by 2 folds and 
DMSO controls (1.25%, 2.5%, 5%) alongwith media controls. All conditions were 
performed in duplicate rows to maintain assay validation. INZ – Isoniazid, PYZ – 
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  4.5.6	  Assay	  Run	  6	  
 
The screen for the compound library was finally setup using and intermediate plate 
prepared from the stock plates. The stock plates had the compound concentration at a 
100mM and were diluted 90: 10 (90µL sterile water and 10µL antibiotic from the 
stock plate). Therefore the concentration of antibiotic in the intermediate plate was 
10mM while the concentration of DMSO was decreased to 10%. Further when the 
antibiotics are added to the assay plate at a volume of 10µL in 200µL cell volume 
(100 µL of cells diluted as 1:1:: media: culture and 100 µL media; making the cells 
diluted as 2:1::media: cell); the DMSO concentration goes down to 0.5% and the 
antibiotic concentration in the final screen is at 0.5mM. The drug screen was run for a 
compound library with ID numbers RW036141- RW036146 and an FDA approved 
drug library from ID numbers RN000205 to RN000216; every plate containing 80 
compounds or drugs respectively. Using the HTS robotic screening with the 
developed assay 480 compounds and 960 FDA approved drugs were screened against 
M. smegmatis for presence of any anti-tubercular activity. Alongwith the library assay 
plates, standard antibiotic plates were run to check effective working of the designed 
assay. Two identical plates were run for every screen including the antibiotic 
standards. The plates were read at every 3 hours over a 24-hour period and incubated 
in a static incubator. 
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Figure 38:  The above assay plates depict the setup for M. smegmatis (mc2155) and M. 
smegmatis (pSMT3_egfp) with serially diluted standard antibiotics by 2 folds. All 
conditions were performed in duplicate rows to maintain assay validation. INZ – 















	   106	  
 
Figure 39:  The above assay plates depict the setup for screening library compounds 
and drugs with the columns 1 and 12 as positive controls while the columns 2-11 had 
different compounds/drugs in each well. 
  
4.5.7	  Assay	  Run	  7	  
 
The FDA drug library was run in two batches stock plates. The screen, which was run 
for plate ID RN000205 - RN000210, gave several hits representing novel inhibitory 
activity against M. smegmatis. The compounds were then used to do a dose response 
study to determine the minimum inhibitory concentration (M.I.C) for that particular 
drug. The initial concentration used during screening was 0.5mM; which showed a 
growth inhibition at or below 50%; therefore deeming the drug as being effective. For 
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fold dilution of 0.5mM; which presented concentrations as 0.166666667mM as the 
maximum concentration and moving to ten 3-fold dilutions of the same from well 2 to 
11. The first column having a positive control (M.smegmatis without antibiotic) and 




Figure 40:  The above assay plates depict the setup for a dose response study of 
selected FDA approved drugs (A-G) serially diluted (3-fold) from 2-11; with column 
1 as a positive control and column 12 as a negative control. A. Tamoxifen citrate, B. 
Meclocycline sulfosalicylate, C. Clomiphene citrate salt, D. GBR 12909 
dihydrochloride, E. Sulocitidil, F. Fendiline hydrochloride, G. R- (-)- Apomorphine 
hydrochloride hemihydrate 
The values attained from the above mentioned assays in terms of relative fluorescence 
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period was used to attain growth curves, survival percentages and percentage activity 
of the drugs in variation with doses. 
4.6	  Statistical	  Validation	  of	  Assays	  
 
All assays which were run were statistically validated for their quality using Z’ factor 
values. The Z’factor mainly depicts the total separation between values of both 
positive and negative controls and the error within each control; describing the 
available signal window. The formula for calculating the Z’ factor values is  
 
                                        
where σ+c, σ-c, µ+c and µ-c are the standard deviation (σ) and the averages (µ) of the 
positive (+c) and negative (-c) controls. 
 
The values of Z’ factor depicts how good or bad an assay is in terms of its reliability. 
In order for an assay to be ready for screening, the Z` should be at the very least 0.5, 
and much more preferably ≥ 0.6. If the Z` is <0.6, the assay quality is not good or 





Page 1 of 3 
Getting an Ass y HTS-ready: the Z` Factor 
 
Definition of Z` 
 
When screening for inhibitors of a target, the metric used to determine the optimal signal window is the 


















σσ  (1) 
 
 
where σ+c, σ-c, µ+c, and  µ-c are the standard deviations (σ) and the averages (µ) of the positive (+c) and 
negative (-c) controls.   
 
The Z` factor describes the available signal window for an assay in terms of the total separation 
between negative and positive controls minus the error associated with each type of control.  For a well 
defined signal window, Z` should be greater than 0.5; that is, the sum of the errors of the controls 
























Parameters for above plot: 
 
In this example, Z` = 0.64, or 64% of the total 
potential signal window is available to define when a 
tested compound in a screen behaves significantly 
differently from either control.  Note that for this 
example, the fold-difference between the positive & 




Separation between negative 
& positive controls (between 
two red solid lines) = 100% 
of potential signal window 
Dashed black line = 3 
standard deviations from the 
average of the negative 
controls  
Dashed black line = 3 
standard deviations from the 
average of the positive 
controls  
Actual signal window = separation 
between two dashed error lines = 64%.   
Parameter Value (arbitrary activity units) 
Avg of Neg Ctrls 200 
Avg of Pos Ctrls 68 
Fold-diff bwn Neg & 
Pos Ctrls 2.9 
Std. Deviation of Neg 
Ctrls 13 
Std. Deviation of Pos 
Ctrls 3 
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5. RESULTS	  
5.1	  Assay	  Optimisation	  
	  
The primary experiment was designed to test which plasmid was most suited for 
performing antimycobacterial activity screens for M. smegmatis. The experimental 
conditions and related results as shown in Fig. 41, presented M. smegmatis 
(pSMT3_egfp) as a better candidate to proceed as a strain for the screening assay. The 
major reason being that the GFP production was not conditional to the selective 
antibiotic reducing the chance of the antibiotic affecting the screening results. The 
pMind_gfp strain had a conditional production in the presence of tetracycline. Also 
the results from the above assay run revealed that the medium used for growing the 
culture and diluting the cells that is tryptic soy broth (TSB) and trypticase soy broth 
was affecting the level of fluorescence for unknown reasons. Therefore for the 














     
 




Figure 41: Graphs representing survival percentages of M. smegmatis (mc2155), 
pSMB_egfp and pMind_gfp. Survival curves for pMind_gfp are represented for 
varying concentration of tetracycline (2.5ng/ml – 25ng/mL) with an M. smegmatis 
(mc2155) control. Survival curves for pSMT3_egfp represent varying conditions of 
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5.2	  Assay	  Standardisation	  
	  
After the determination of a model strain to be used for the screens, assays were setup 
using standard drugs to determine cell volume, concentration and drug volume, which 
would give effective results. The graphs in Fig 42 represent the cell dilutions, which 
were standardized against standard drugs that are Isoniazid, Ethambutol, 
Pyrazinamide and Rifampicin. The cells at 1:1 dilutions although showed a better 
response and values for fluorescence than undiluted cell, it quickly became clear that 
due to high cell load the fluorescence levels were quickly saturated after several 
cycles leading to inconclusive results (Fig. 42a.). When the cells were further diluted 
to a 2:1, media to cells ratio it was seen that there was a much clearer difference in 
cell survival percentage values versus antibiotic concentration. Therefore for the 
purpose of further assay development the cell concentrations were taken at a 2:1 
dilution (Fig. 42 b.). The drug standards run alongwith the compound screens also 















    
                                a                                                                      b 
    
                                   c                                                                             d           
Figure 42: Graphs representing survival and inhibition percentages of M. smegmatis 
(pSMT3_eGFP) against standard drugs like Isoniazid, Ethambutol, Pyrazinamide and 
Rifampicin over dilutions of 2 folds. a. and b. Representing the survival percentages 
during early optimization of cell concentration (1:1 and 2:1 respectively). c. and d. 
represent the drug standards run during the compound library screening. Z’ factor – 
0.6-0.7 
pSMB_egfp (drug standard 08-05)
Concentration of Antibiotic


















pSMB_egfp (drug standard 13-05)
Concentration of Antibiotic
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5.3	  HTS	  screen	  against	  diversity	  library	  
The compound screen resulted in many “Hits”, which were considered to be all those 
compounds, which caused the survival percentage of M. smegmatis (pSMT3_egfp) to 
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Figure 43: Graphs representing survival percentages of M. smegmatis (pSMT3_egfp) in the 
presence of various compounds from the compound library. Each graph is representative of a 
different compound plate as labeled from RW036141- RW036146. The X-axis of the graph 
represent the well numbers on the assay plate containing specific compounds, Y- axis has the 
survival percentages. The cut-off line for screening was taken at 50% survival rate in the 
presence of the compound. Z’ factor- 0.5-0.7 
All the “Hits” from the above-mentioned assay were considered as novel compounds 
for further study as none of them have been previously studied in context with 







Compound Name Percentage 


















G11 3-(2-fluorophenyl)-1-[4-(methylsufanyl) phenyl]-2- 
25.81 












sulfanyl}-N- (2-ethyl-6-methylphenyl) acetamide 
12.99 
Table 3: The table mentioned above has all the “hits” from the compound screen, the 
highlighted ones have shown some relative study or chemical properties which could lead to 




The plate had one hit with a 37.62% survival percentage. The compound identified 
was in the well C04. The chemical name of the compound is 2-(-4-chloro-3-





The plate had four hits with two of them at a lower survival percentage of 26.3%	  and	  
25.81% for B07 and G11 respectively, while the other two were at  
37.62% and 39.75%	  survival percentages for F07 and E04 respectively. The compound 
names are N-­‐[4-­‐({[(3-­‐ethoxybenzoyl)amino]carbothioyl}amino)phenyl]acetamide	   (B07),	   3-
	   116	  
(2-fluorophenyl)-1-[4-(methylsufanyl) phenyl]-2-propen-1-one (G11), 2-mesityl-1-
oxo-1H-inden-3-yl-acetate (F07) and 1-{2-[(2,4-
dicholorophenyl)(phenyl)methoxy]ethyl}2-methyl-4,5-hydro-1H-imidazole	   (E04), 




The plate had two hits with a 36.40 % and 40.45%	  survival percentage in well C04 and 
F02. The chemical name of the compound is N- (4-butylphenyl)-N’- (2,2-
dimethoxyethyl) thiourea and 6-­‐[5-­‐2-­‐pyridinyl)-­‐4,5-­‐	   dihydro-­‐1H-­‐pyrazol-­‐3-­‐yl]-­‐2H-­‐1,4-­‐




The plate had one hit with a 12.99 % survival percentage. The compound identified 
was in the well C02. The chemical name of the compound is 2-{[4-amino-5- (2-
cholorophenyl)-4H-1, 2,4-triazol-3-yl] sulfanyl}-N- (2-ethyl-6-methylphenyl) 
acetamide, with the chemical structure as mentioned in Fig 44. 
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Figure 44: Compound hits 
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5.4	  HTS	  screen	  against	  FDA	  library 
The FDA drug screen resulted in many “hits”, that is those drugs, which caused the 
survival percentage of M. smegmatis (pSMT3_egfp) to be at and below 50% value 
presented in Fig. 45. The “Hits” attained from the above shown assay had many 
generic antitubercular drugs along with different FDA drugs available for treating 
other diseases.  
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Figure 45: Graphs representing survival percentages of M. smegmatis (pSMT3_egfp) in the 
presence of various compounds from the FDA drug library. Each graph is representative of a 
different compound plate as labeled from RN000205- RN000210. The X-axis of the graph 
represent the well numbers on the assay plate containing specific FDA drugs, Y- axis has the 
survival percentages. The cut-off line for screening was taken as 50% survival rate in the 
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The “hits” mentioned below are all those drugs which produced a survival percentage 
of less than 50%. Out of the below mentioned drugs, several drugs were shortlisted on 
basis of novelty of use against Mycobacterium after thorough literature search and 





plate Drug Name 
Percentage Survival 
(%) 
RN000205 A2 Azaguanine-8 49.62614664 
  A3 Allantoin 105.3027486 
  C9 Ethambutol 43.52914306 
  D2 Chloramphenicol 52.16180109 
  D7 Troleandomycin 47.23993656 
  D8 Pyrimethamine 51.44009912 
  D11 Niclosamide 7.520399947 
  G8 Miconazole 13.95385752 
  H9 Thioridazine hydrochloride 13.96079893 
RN000206 C2 
R (-) Apomorphine hydrochloride 
hemihydrate 29.2392455 
  D4 Ciprofloxacin hydrochloride monohydrate 18.45764194 
  E5 Tioconazole 11.23998443 
  E7 Mefloquine hydrochloride 17.6479618 
  E8 Isoconazole 10.92490978 
  F7 Astemizole 10.33337356 
  G6 Chlorotetracycline hydrochloride 10.44025611 
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  G7 Tamoxifen citrate 11.96387987 
  H2 Erythromycine 17.69592958 
  H5 Josamycin 18.05917104 
  H10 Dihydrostreptomycin sulfate 23.47853454 
  H11 Gentamicine sulfate 28.46001794 
RN000207 E9 Trimethoprim   49.14275185 
  G2 Norfloxacin 28.31717438 
  G8 Clemizole hydrochloride 16.49153847 
  H9 Lomefloxacin hydrochloride 21.33615203 
RN000208 C8 Clotrimazole 10.70325838 
  C11 Fendiline hydrochloride 27.41299691 
  E7 Perhexiline maleate 18.10390467 
  G5 Econazole nitrate 9.02389887 
  G8 Oxytetracycline dihydrate 25.53351592 
  H4 Trifluoperazine dihydrochloride 17.59590399 
  H6 Minocycline hydrochloride 7.293698781 
  H10 Clofilium tosylate 15.58719476 
RN000209 A2 Streptomycin sulfate 19.67469832 
  E5 Metergoline 42.36107314 
  E9 Bepridil hydrochloride 35.25149373 
  E11 Benzbromarone 42.13418206 
  F6 Methiothepin maleate 29.3687273 
  F7 Clofazimine 23.52110751 
  G2 Lidoflazine 27.76877416 
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  G6 Mitoxantrone dihydrochloride 25.00702933 
  G7 GBR 12909 dihydrochloride  20.28253993 
  G9 Dequalinium dichloride 9.077205452 
  H6 Amikacin hydrate 17.57039091 
  H8 Clomiphene citrate 11.67063694 
  H10 Prochlorperazine dimaleate 26.97953685 
RN000210 A9 Butoconazole nitrate 12.48838345 
  A10 Amiodarone hydrochloride 24.80763778 
  C2 Suloctidil 14.38444091 
  C3 Zotepine 56.03883472 
  F5 Linezolid 23.5113094 
  F7 Meclocycline sulfosalicylate 8.915604769 
  F8 Meclozine dihydrochloride 30.91774694 
  G6 Tosufloxacin hydrochloride 19.33072913 
  G8 Rifapentine 13.18458897 
  H7 Primaquine diphosphate 35.23359113 
 
Table 4: The table mentioned above has all the “hits” from the FDA drug screen, the 
highlighted drugs are the ones, which were researched and found to be novel as per 
the literature. Therefore the drugs were taken further to do a dose response analysis. 
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Figure 46: Graphs representing survival percentages of M. smegmatis (pSMT3_egfp) in the 
presence of various compounds from the FDA drug library. Each graph is representative of a 
different compound plate as labeled from RN000211- RN000216. The X-axis of the graph 
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survival percentages. The cut-off line for screening was taken at 50% survival rate in the 
presence of the compound. Z’ factor – 0.5-0.8 
The FDA drug screen resulted in many “Hits”, which were considered to be all those 
drugs, which caused the survival percentage of M. smegmatis (pSMT3_egfp) to be at 
and below 50% value. The “Hits” attained from the above shown assay had many 
generic antitubercular drugs along with different FDA drugs available for treating 
other diseases. The “hits” mentioned below are all those drugs which produced a 
survival percentage of less than 50%. Out of the below mentioned drugs, several 
drugs were shortlisted on basis of novelty of use against Mycobacterium after 
thorough literature search and review. The Highlighted drugs in the below mentioned 





plate Drug Name 
Percentage Survival 
(%) 
RN000211 B8 Vancomycin hydrochloride  20.21 
  D2 Fluoxetine hydrochloride  50.13 
  D10 Imipenem  52.635 
  E6 Rifampicin  11.645 
  E7 Ethionamide  49.29 
  G5 Tobramycin  17.85 
  H4 Pentamidine isethionate  16.19 
 
H11 Prenylamine lactate  30.765 
RN000212 E6 Carbadox  38.425 
  F7 Demecarium bromide  12.615 
RN000213 A7 Oxiconazole Nitrate  9.565 
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  A11 Pinaverium bromide  10.705 
  C7 Nisoldipine  32.1 
 E7 Thimerosal  7.1 
 
F11 Cefmetazole sodium salt  51.06 
 G6 Methyl benzethonium chloride  10.815 
  G9 Benzethonium chloride  10.815 
RN000214 D4 Demeclocycline hydrochloride  9.045 
  F8 Alexidine dihydrochloride  14.485 
  H3 Propidium iodide  17.14 
RN000215 A11 Sulconazole nitrate  8.695 
  B2 Auranofin  7.865 
  B10 Moxalactam disodium salt  32.585 
  D5 Novobiocin sodium salt  22.62 
  E10 Clinafloxacin  16.195 
  G3 Raloxifene hydrochloride  9.535 
  G8 Paromomycin sulfate  27.56 
RN000216 C7 Fluspirilen  9.58 
  E6 Thonzonium bromide  11.115 
  G5 Phenoxybenzamine hydrochloride  9.44 
  H3 Toremifene  10.875 
 
Table 5: The table mentioned above has all the “hits” from the FDA drug screen, the 
highlighted drugs are the ones, which were researched and found to be novel as per 
the literature.  
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5.5	  Dose	  response	  against	  selected	  drugs	  
	  
The screening assay conducted before presented all of the selected drugs to be active 
at the concentration of 0.5mM. The dose response assay was performed to check for 
lower concentrations at which inhibition could occur. 
As shown in fig. 47, Meclocycline sulfosalicylate showed activity at a much lower 
concentration of 0.00205mM. While drugs such as Clomiphene citrate and 
sulocitidil showed a dip in the growth of the bacillus at a concentration of 
0.0555mM. Tamoxifen citrate showed an inhibitory concentration of 0.166mM. 
While for Fendiline hydrochloride the concentration range seems not to have 
covered the inhibitory concentration that leads us to believe that the primary 
concentration of drug used that is 0.5mM could be the minimum inhibitory 
concentration for it. 
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Figure 47 : Graphs representing the dose response curves of M. smegmatis (pSMT3_egfp) in the 
presence of various compounds from the FDA drug library, which showed activity in the first 
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6.	  DISCUSSION	  




Compounds similar to the said thiazole with different side groups have shown 
antibacterial activity. Nitrothizolyl is an antiparastic, which has been seen to be 
mircobicidal for M. tuberculosis, acting on it by disrupting its membrane potential. 
Analogues of 5- nitrothioaolyl and its derivatives are very potent against M. 
tuberculosis. Therefore the said compound in relation might have a similar mode of 
action due to its structure similarity and potency against Mycobacterium sps. 
(Jeankumar et. al.,2012) 
6.1.2	  2-­‐mesityl-­‐1-­‐oxo-­‐1H-­‐inden-­‐3-­‐yl-­‐acetate	  
 
The compound is inhibits the complement system and biosynthesis of prostaglandins 
(Asghar et. al.,1986, Van der Goot et. al.,1984).  Interestingly it is known to act as an 
insecticide against pear psylla, a sap-feeding insect (family cicada)  due to its 
surfactant activity, which is inhibitory for the insect (Formigoni, 1980). In humans 
there are four surfactant proteins (SP-A to D). Alveolar surfacatants interact with 
Mycobacterial surface proteins via their CRD domains modulating the bacterial 
viability, transcriptional progress and uptake and fate of the microbe in macrophages. 
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The surfactants initiate ingestion of infected epithelial cells and free bacilli by the 
macrophage. The disruption of surfactant metabolism causes the progression of 
tuberculosis from latent to a secondary infection (Chroneos et. al.,2009). The protein 
SP-D works by binding and masking the terminal mannose cap of ManLAM on the 
bacterial surface directing phagocytosis and promoting phagosome maturation. 
(Ferguson et. al., 2006). The modulatory activity of this surfactant like compound 




Imidazolines have been known to act as antagonists to muscarinic M3 receptors, 
which are mainly acetylcholine receptors. These up regulate the phospholipase C and 
regulate intracellular calcium levels for signaling pathways. No direct link has been 
proved as yet regarding the regulation of calcium levels with infectivity with 
Mycobacterium but it could be one of the mechanisms through which the compound 




The chalcones, are an important category of antimycobacterials; 23 synthesised 
chalcones (including 4-methyl thiochalcones) have shown a 98% reduction in relative 
light unit (RLU) in M. tuberculosis (Sivakuma et. al.,2010). They are mainly effective 
against phosphotyrosine phosphatase (PTP), which are majorly involved in cell 
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signaling pathways. In Mycobacterium there are two PTPs, PtpA and PtpB. PtpA uses 
VPS3313 as a substrate to avoid fusion of the phagolysosome therefore making it and 
is an essential protein for persistence of the bacillus. Attenuated growth of 
Mycobacterium has been seen on inactivation of the PtpA gene (Mascarello et. al., 
2010; Chiaradia et. al., 2008). The nature and position of the substituent in the ring A 
and the hydrophobicity and planarity of napthyl groups ring B are seen as 
predominant factors for the inhibition of Ptp A (Chiaradia et. al., 2008). Chalcones 
are competitive inhibitors of PtpA and B, where polar interactions play a key role in 
orienting the molecule within the protein-binding site. The compound tends to bind in 
a narrow channel close to the catalytic site at a cysteine residue at the 160 positions. 
(Chiaradia et. al.,2012).  
6.1.5	  N-­‐(4-­‐butylphenyl)-­‐N’-­‐(2,2-­‐dimethoxyethyl)thiourea	  
 
The compound has yet not been worked upon directly. But related compounds such as 
N-(4-butylphenyl)-N'-[1-(methoxymethyl)propyl] thiourea , is known to have 
inhibitory activity against glycogen synthase kinase 3 (GSK-3) by inhibiting its 
transport from the cell nucleus to cytoplasm. GSK-3 has been involved in causing 
major diseases such as alzheimers, cancer etc. (Yook et. al.,2010). In Mycobacterium, 
glucosyltansferase uses UDP- glucose as a sugar donor to elongate the α (1 to 4) 
glucans. It is mainly implicated in the biosynthesis of 6-O-methylglucosyl 
lipopolysaccahrides. The gene coding for glycogen synthase in Mycobacterium, 
Rv3032 does not cause lethality in the organism if disrupted but does affect the 
multiplication and persistence and increases its sensitivity to validamycin A; which is 
a TreS inhibitor. It has a supporting gene glgA, which manages to help the bacillus 
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survive, but knocking both these genes causes organism death leading us to the fact 
that atleast one functional copy of either gene is necessary for its survival.  
Another compound similar to the said compound is an inhibitor of epoxy hydrolase 
and is used for the treatment of hypertension (Kroetz et. al,2003). Mycobacterium has 
six epoxide hydrolases, which has a role in converting epoxides into trans 
dihydrodiols (Biswal et. al.,2008). The enzymes play a role in virulence, 
detoxification and regulation of signaling molecules and defense systems in 
mammals. (Johansson et. al.,2005) 
The exact mechanism of action has not been reported, but it could be possible that 
since similar compounds have the said inhibitory actions they could be similar in 




Acetamides have been known to have an antitubercular effect the mode of action of 
the compound could be predicted. Acetamides act against the cell wall, disrupting the 
cell wall biosynthesis process. Sulfonyl acetamide derivatives are a new class of 
antibiotics that mimic the transition state of β-ketoacyl synthase (KAS) of fatty acid 
biosynthesis (Ghosh et. al.,2008). N-octanesulfonylacetamide (OSA) causes reduction 
in the accumulation of mycolic acids in BCG and Mycobacterium Avium complex 
(MAC) by affecting the FAS system. Although OSA also acts on the cell wall similar 
to isoniazid it has been seen to inhibit isoniazid resistant M. tuberculosis and MAC 
(Parish et. al.,2001). N- phenylphenoxyacetamide derivatives inhibits a transcriptional 
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repressor, EthR which causes an innate resistance to second line drugs mainly 
ethionamide (Flipo et. al.,2012).  Ethionamide like isoniazid also acts on the cell wall 
but via a different mechanism, that is by getting activated through an FAD containing 
enzyme which catalyses NADPH and converts ETA to ETA-S-oxide through an 
oxygen dependant monoxygenation. (Parish et. al.,2001). Although no exact structure 
matches were obtained against the compound alongwith the absence of any specific 
biological roles, the compound appears to be novel. 
6.2	  FDA	  Drugs	  
 
The FDA drugs which came out as successful inhibitors of M. smegmatis were a 
varying mixture ranging from anti cancer drugs to drugs used to treat skin conditions. 
Tamoxifen citrate is a lipophilic drug belonging to a class of non-steroidal 
triphenylethylene derivatives (Elnaggar et. al.,2009) and is a hormone therapy drug 
that is currently being prescribed for breast cancer chemotherapy causing a decrease 
in the proliferation of breast tissue. 45% of patients treated with tamoxifen showed a 
decrease in new tumor incidence after 5 or more years of use while 28% had decrease 
in benign tumors and lesions (De Souza Sales Jr et. al.,2007). It also has been shown 
to decrease risk of heart disease and osteoporosis, by decreasing the level of TNF R2, 
which plays a role in TNF α induced cardiac injury. Although the major mechanism 
of action in protecting the cardiac tissue is by increasing mitochondrial respiration, 
which is the major source of energy for the cardiac tissue. It does so by increasing the 
superoxide scavenging activity in mitochondria (Zhao et. al.,2006). Clomiphene 
citrate, which belongs to the same class as tamoxifen citrate is used to induce 
ovulation. Although a study comparing the efficacy of both these drugs declared 
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tamoxifen to be more effective as a hormone therapy drug to induce ovulation leading 
to more number of pregnancies and lower rates of miscarriages (Boostanfar et. 
al.,2001).Clomiphene citrate is although a safer choice to use as a fertility drug and 
acts as an estrogen agonist as well as antagonist. Agonistic properties of the drug 
occur when the endogenous estrogen level is very low while in other cases it acts as 
competitive estrogen antagonist. Clomiphene binds to nuclear estrogen receptors for a 
longer times interfering with the regular cycling and replenishment of the ER; while 
at the hypothalamic level it decreases the hypothalamic estrogen receptors causing an 
overcompensatory response which increases the gonadotropin releasing hormone 
(GnRH) causing an increase in ovarian follicular activity (Pfeifer et. al.,2013). It has 
also been traditionally used in the treatment of non-obstructive oligospermia and 
reversal of hypogonadism via gonadotropin secretion (Ioannidou-Kadis et. al.,2006; 
Kaminetsky and Hemani,2009). Another similar drug Raloxifen which is also a 
competitive estrogen receptor modulator (Kathryn Senior, 1999) was compared with 
Tamoxifen which again showed better results for estrogen replacement therapy by 
decreasing the circulating estrogen and decreasing chances of osteoporotic fractures 
in menopausal women (Khovidhunkit and Shoback,1999); but at a higher risk of 
causing endometrial cancer on long term use (Boss et. al., 1997). The drug raloxifen 
has been seen to act as an antiviral agent against patients with chronic hepatitis C by 
directly inhibiting the replication system of the virus (Furusyo et. al.,2012). 
Several antibacterial and antiseptics also were active against Mycobacterium such as 
meclocylcline sulfosalicylate which is majorly used as a topical ointment for treating 
skin conditions such as acne (Borglund et. al.,1991) and mostly used in combination 
with other drugs such as benzoyl peroxide to observe 82% success rate and decrease 
in skin lesions (Knutson et. al.,1981). Demeclocycline hydrochloride is a tetracycline 
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derivative highly effective against microbes with a very good bioavailability (Dong 
et. al.,2013). Although being an Anti Diuretic Hormone (ADH) antagonist it is 
majorly used to increase excretion of solute free water to treat patients with 
inappropriate hyper secretion of ADH (Garwicz,1976) and cancer patients who 
develop hyponatremia during treatment (Trump,1981). Benzethonium chloride is 
another drug, which is used as a preservative for vaccines (Olson et. al.,1964) and a 
disinfectant in hospitals. It has also been seen that it acts as an inhibitor of HERG 
potassium channels, which could cause risks of cardiac arrythmia (Long et. al.,2013). 
In recent times through similar protocol of HTS the drug has shown a novel 
anticancerous activity against human cancer cell lines inducing apoptosis and 
activation of caspases. It caused loss of membrane potential on the mitochondrial 
membrane and and increase in calcium (Ca2+) level leading to cell death (Yip et. 
al.,2013).  
GBR 12909 dihydrochloride commercially known as Vanoxerine is an 
antiarrythmatic drug used to terminate induced atrial flutter and atrial firbrillation 
(AF). Earlier use involved treatment for Parkinson’s and depression, but had a low 
efficacy while in case of reducing atrial flutter it has an excellent efficacy and safety 
profile as it has multichannel blocking properties (Cakulev et. al.,2012). It interrupts 
an atrial flutter by blocking the circulating reentrant wave front in an area of slow 
conduction (Szasz et. al.,2007). It has also been seen to be useful in treating cocaine 
addiction by attaching to the dopamine transporter (DAT) for a longer time compared 
to cocaine (Rothman et. al.,2008). Cocaine has a reinforcing effect mediated by 
dopamine on dopaminergic neurons. It binds to monoamine transporters inhibiting 
reuptake of their respective neurotransmitter (that is dopamine) therefore increasing 
the extracellular level of dopamine causing stimulation of postsynaptic dopamine 
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receptors (Andersen, 1989). R(-) Apomorphine hydrochloride hemihydrate is a D1 
and D2 dopaminergic agonist, useful for diagnosing idiopathic Parkinson’s disease 
and other Parkinson plus syndrome (Warraich et. al.,2009). It acts as an indicator of 
dopaminergic responsiveness and is a dopamine receptor agonist with potent anti-
Parkinson action (Hughes et. al.,1990). Apomorphine is known to alleviate akinesia 
(slowness of initiation), rigidity and tremor (Muguet et. al.,1995) when administered 
subcutaneously(Frankel et. al.,1990).  
Sulocitidil among many other drugs such as aspirin, dipyridamole, sulfinpyrazone etc. 
is a platelet-inhibiting drug. It is mainly used to elevate thrombosis, which is a cause 
for strokes sometimes followed by transient ischemic attacks (neurological 
dysfunction due to loss of blood flow) (Gent et. al.,1985). It is a potent 
antiaggregating drug whose common mechanism of action is inhibition of 
phosphodiesterase activity and increase of cyclic AMP (Roba et. al.,1975). It has been 
understood that sulocitidil is also a calcium antagonist, since calcium ions play a 
major role in PG2 synthesis it causes a slow efflux of calcium into endothelial cell 
leading to prolonged stimulation and release of prostacyclin (PG1); a potent inhibitor 
of platelet aggregation (Boeynaems et. al.,1987). Fendiline hydrochloride is another 
calcium antagonist  (Nayler and Horowitz, 1983) used as an anti-anginal agent for the 
treatment of coronary heart disease. It inhibits trans membrane calcium current and 
causes smooth muscle relaxation therefore providing cardio protection (Bayer and 
Manhold,1987). It has been studied to have possible anti cancer properties as it 
inhibits downstream signaling of constitutively active K-Ras, which is important for 
cell proliferation, cell growth, differentiation and survival. In oncogenic cells mutant 
Ras protein is produced, which when blocked has been understood to block cancer 
cell proliferation in cancer cell lines expressing the mutant Ras protein (Van der 
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Hoeven et. al.,2013). Pinaverium bromide is a quaternary ammonium compound used 
to treat intestinal motor disorder and irritable bowel syndrome. It decreases colonic 
response to food and has a high efficiency to postprandial (after eating) inhibition of 
muscular contractions (Bouchouchal et. al.,2000; Christen, 1990). It is a L- type 
calcium blocker which binds to α-1 subunit of Ca2+ channel and inhibits the 
contraction of smooth muscles induced by cholecystokinin (CCK) (Boyer et. 
al.,2001).Another calcium antagonist is nisoldipine which is helpful in treating severe 
ventricular dysfunction. It has systemic coronodilatory function helpful to patients 
with left ventricular dysfunction (Rousseau et. al.,1994). Its administration has lead to 
improved exercise tolerance, improved diastolic filling probably related to 
improvement of chronic ischemic areas (Pouleur And Rousseau, 1993). 
Interestingly, drugs that have shown activity against M. smegmatis have repetitive 
classes of drugs having similar modes of action. This could be an indicative of 
specific drug target areas influencing cell death in Mycobacterium. The mechanism of 
action of individual drug against Mycobacterium has yet to be explored, but it is 
interesting to see that the drugs are grouped in terms of mode of action and the target 
on the host cell. The only possible known mechanism of action studied till date is that 
of calcium channel blockers which are accounted for among the drug “hits” reported. 
Calcium ions and Mycobacterium have had a long-standing relationship involving its 
role in pathogenesis and host-pathogen interaction. Calcium plays an important role in 
the fusion of phagosome with the lysosome in neutrophils and macrophages (Vergne 
et. al.,2003). Calcium ions along with potassium ions have a significant role in 
phagolysosome biogenesis and killing of the bacillus. Both ions depend on active 
transport processes for transport across membranes. When the bacillus is 
phagocytosed the phagosome is made up of the plasma membrane that is rich in 
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calcium and potassium ion transport pumps. The bacteria use these pumps to transport 
the calcium and potassium ion pumps to pump out the ions from within the 
phagosome to the cytoplasm of the cell. During the fusion of the phagosome to the 
lysosome the low concentration of calcium and potassium ions prevents acidification 
of the phagolysosome due to absence of hydrogen ion influx across a concentration 
gradient; therefore protecting the bacillus form getting killed (Martins et. al.,2008). it 
has been seen that blockage of L- and R- type voltage gated calcium channel (VGCC) 
plays a regulatory role for immune response by activation of calcium channel 
dependent mechanism favoring inflammatory response. In vivo blockage of VGCC in 
M. tuberculosis infected mice using antibodies increase the intracellular calcium and 
decreased bacterial loads (Gupta et. al.,2009). The exact mechanisms for the drugs 
and compound “hits” are still to be explored through various strategies, but the assay 
using a fluorescent strain of M. smegmatis has been designed and optimized 
successfully to give a robustly and reliably screen out compounds against 
Mycobacterium. 
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Figure 19. The prevalence and incidence rates of tuberculosis in 2009. A. Estimated 
rates of tuberculosis; B. Estimated HIV prevalence in new tuberculosis cases (Lawn 
and Zumla, 2011) 
Figure 20.The cell wall components of Mycobacterium tuberculosis. (Abdallah et. al., 
2007) 
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Figure 28.A flowchart representing drug discovery strategies describing the drug 
development from drug to target and from target to drug. The two strategies overlap at 
a level for in vivo studies. HTS – High throughput screening. (Sala and Hartkoorn, 
2011) 
Figure 29. pMind_gfp plasmid with a Kanamycin resistance gene and the tetracycline 
gene for controlled production of GFP in the cell (Blokpoel et. al.,2005) 
 
Figure 30.The pSMT3_sgfp plasmid with a Mycobacteria shuttle vector pSMT3; 
hygromycin marker, and enhanced GFP codon with a hsp60 promoter (Humphreys et. 
al., 2006) 
 
Figure 31. The above assay plates depicts the setup for a positive control plate with 
wild type M. smegamtis (mc2 155) in the presence and absence of both hygromycin 
and kanamycin; to check for innate resistance. 
 
Figure 32. The above assay plates depict the setup for M. smegmatis (pSMT3_egfp) 
with varying conditions; presence and absence of Tween 80 and hygromycin. 
 
Figure 33. The above assay plates depicts the setup for M. smegmatis (mc2155) and 
M. smegmatis (pMind_gfp) with varying conditions; presence of Kanamycin and 
tetracycline. Two plates were setup in the same manner with different strains to have 
half of the plate as a duplicate for the experimental validation. 
 
Figure 34. The above assay plates depicts the setup for M. smegmatis (mc2155), M. 
smegmatis (pSMB_egfp) and M. smegmatis (pMind_gfp) with varying conditions; 
presence of Kanamycin and tetracycline. All conditions were performed in duplicate 
rows to maintain assay validation. 
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Figure 35. The above assay plates depict the setup for M. smegmatis (mc2155) and M. 
smegmatis (pSMT3_egfp) with serially diluted standard antibiotics by 2 folds. All 
conditions were performed in duplicate rows to maintain assay validation. INZ – 
Isoniazid, PYZ – Pyrazinamide, EMB – Ethambutol, RIF – Rifampin 
 
Figure 36. The above assay plates depict the setup for M. smegmatis (mc2155) and M. 
smegmatis (pSMT3_egfp) with serially diluted standard antibiotics by 2 folds and 
DMSO controls alogwith media controls. All conditions were performed in duplicate 
rows to maintain assay validation. INZ – Isoniazid, PYZ – Pyrazinamide, EMB – 
Ethambutol, RIF – Rifampin. 
 
Figure 37. The above assay plates depict the setup for M. smegmatis (mc2155) and M. 
smegmatis (pSMT3_egfp) with serially diluted standard antibiotics by 2 folds and 
DMSO controls (1.25%, 2.5%, 5%) alongwith media controls. All conditions were 
performed in duplicate rows to maintain assay validation. INZ – Isoniazid, PYZ – 
Pyrazinamide, EMB – Ethambutol, RIF – Rifampin. 
 
Figure 38. The above assay plates depict the setup for M. smegmatis (mc2155) and M. 
smegmatis (pSMT3_egfp) with serially diluted standard antibiotics by 2 folds. All 
conditions were performed in duplicate rows to maintain assay validation. INZ – 
Isoniazid, PYZ – Pyrazinamide, EMB – Ethambutol, RIF – Rifampin. 
 
Figure 39-The above assay plates depicts the setup for screening library compunds 
and drugs with the columns 1 and 12 as positive controls while the columns 2-11 had 
different compounds/drugs in each well.  
 
Figure 40. The above assay plates depict the setup for a dose response study of 
selected FDA approved drugs (A-G) serially diluted (3-fold) from 2-11; with column 
1 as a positive control and column 12 as a negative control. A. Tamoxifen citrate, B. 
Meclocycline sulfosalicylate, C. Clomiphene citrate salt, D. GBR 12909 
dihydrochloride, E. Sulocitidil, F. Fendiline hydrochloride, G. R- (-)- Apomorphine 
hydrochloride hemihydrate 
 
Figure 41. Graphs representing survival percentages of M. smegmatis (mc2155), 
pSMB_egfp and pMind_gfp. Survival curves for pMind_gfp are represented for 
varying concentration of tetracycline (2.5ng/ml – 25ng/mL) with an M. smegmatis 
(mc2155) control. Survival curves for pSMT3_egfp represent varying conditions of 
hygromycin and Tween-80 with M. smegmatis (mc2155) as a control. 
 
Figure 42-Graphs representing survival and inhibition percentages of M. smegmatis 
(pSMT3_eGFP) against standard drugs like Isoniazid, Ethambutol, Pyrazinamide and 
Rifampicin over dilutions of 2 folds. a. and b. Representing the survival percentages 
during early optimization of cell concentration (1:1 and 2:1 respectively). c. and d. 
represent the drug standards run during the compound library screening. Z’ factor – 
0.6-0.7. 
 
Figure 43.Graphs representing survival percentages of M. smegmatis (pSMT3_egfp) in 
the presence of various compounds from the compound library. Each graph is 
representative of a different compound plate as labeled from RW036141- RW036146. 
The X-axis of the graph represent the well numbers on the assay plate containing 
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specific compounds, Y- axis has the survival percentages. The cut-off line for 
screening was taken at 50% survival rate in the presence of the compound. Z’ factor- 
0.5-0.7. 
 
Figure 44. Compound hits 











Figure 45. Graphs representing survival percentages of M. smegmatis (pSMT3_egfp) 
in the presence of various compounds from the FDA drug library. Each graph is 
representative of a different compound plate as labeled from RN000205- RN000210. 
The X-axis of the graph represent the well numbers on the assay plate containing 
specific FDA drugs, Y- axis has the survival percentages. The cut-off line for 
screening was taken as 50% survival rate in the presence of the compound. Z’ factor 
– 0.5-0.7 
 
Figure 46. Graphs representing survival percentages of M. smegmatis (pSMT3_egfp) 
in the presence of various compounds from the FDA drug library. Each graph is 
representative of a different compound plate as labeled from RN000211- RN000216. 
The X-axis of the graph represent the well numbers on the assay plate containing 
specific FDA drugs, Y- axis has the survival percentages. The cut-off line for 
screening was taken at 50% survival rate in the presence of the compound. Z’ factor 
– 0.5-0.8 
 
Figure 47. Graphs representing the dose response curves of M. smegmatis 
(pSMT3_egfp) in the presence of various compounds from the FDA drug library, 
which showed activity in the first round of screening. Z’ factor- 0.6-0.8 
 
Table 2.  Representing the antibiotics used for tuberculosis, with the MIC values, 
gene and gene products in Mycobacterium (Da Silva and Palomino, 2011) 
Table 3. The table mentioned above has all the “hits” from the compound screen, the 
highlighted ones have shown some relative study or chemical properties which could 
lead to possible understanding of the mechanism of action. 
 
Table 4. The table mentioned above has all the “hits” from the FDA drug screen, the 
highlighted drugs are the ones, which were researched and found to be novel as per 
the literature. Therefore the drugs were taken further to do a dose response analysis. 
 
Table 5. The table mentioned above has all the “hits” from the FDA drug screen, the 
highlighted drugs are the ones, which were researched and found to be novel as per 
the literature. 
